Publications 2025

Abrantes R, Forcados C, Warren DJ, Santos-Ferreira L, Fleten KG, Senra E, Costa AF, Krpina K, Henrique R, Liberg AM, Rawat P, Gelebart P, McCormack E, Bjørge L, Davidson B, Greiff V, Costea DE, Pinto F, Flatmark K, Gomes C, Inderberg EM, Reis CA, Wälchli S (2025)
Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors
6 (9), 102350
DOI 10.1016/j.xcrm.2025.102350, PubMed 40925376

Costa J, Le VL, De Leo A, Ravaioli C, Velasco V, Davidson B, Skeie-Jensen T, Devouassoux-Shisheboran M, Trecourt A, Bartosch C, Rios E, Genestie C, Pautier P, Lebreton C, Guyon F, Babin G, Coindre JM, Le Loarer F, Saut O, Croce S (2025)
Deep Learning Can Accurately Predict the Prognosis of Gynecologic Smooth Muscle Tumors of Uncertain Malignant Potential: A Multicenter Pilot Study
105 (10), 104211
DOI 10.1016/j.labinv.2025.104211, PubMed 40602459

Dagher C, Bjerre Trent P, Alwaqfi R, Davidson B, Ellenson LH, Zhou Q, Iasonos A, Mueller JJ, Alektiar K, Makker V, Feinberg J, Smith E, Kim SH, Hatoum S, Leitao MM, Abu-Rustum NR, Eriksson AGZ (2025)
Effect of substantial lymphovascular space invasion on location of first disease recurrence in surgical stage I endometrioid endometrial adenocarcinoma
35 (4), 101651
DOI 10.1016/j.ijgc.2025.101651, PubMed 40055122

Dagher C, Trent PB, Alwaqfi R, Davidson B, Ellenson LH, Zhou Q, Iasonos A, Mueller JJ, Alektiar K, Makker V, Feinberg J, Smith E, Kim SH, Hatoum S, Leitao MM, Abu-Rustum NR, Eriksson AGZ (2025)
Erratum to 'Effect of substantial lymphovascular space invasion on location of first disease recurrence in surgical stage I endometrioid endometrial adenocarcinoma' [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101651]
35 (9), 101962
DOI 10.1016/j.ijgc.2025.101962, PubMed 40483226

Davidson B, Holth A, Wohlschlaeger J, Pinamonti M, Önal B (2025)
The Diagnostic Role of TFF1, TFF3, FOXA1, CA XII and TRPS1 in Serous Effusions
36 (4), 408-417
DOI 10.1111/cyt.13489, PubMed 40170411

Lindemann K, Siegenthaler F, Lande KT, Casas-Arozamena C, Nebdal D, Rau TT, Hoivik EA, Mueller MD, Gold RM, Imboden S, Davidson B, Krakstad C, Sørlie T (2025)
Prognostic value of assessing ctDNA in patients with endometrial carcinoma - an international multicenter study
195, 98-105
DOI 10.1016/j.ygyno.2025.03.002, PubMed 40081113

Turashvili G, Croce S, Davidson B, Hausladen S, Solheim O, Carinelli S, Lombardi M, Lim D, Devins K, Lin LH, Dias-Santagata D, Young RH, Oliva E (2025)
A Distinctive DICER1-Related Wilms-Like Uterine Tumor: A Report of Eight Cases
38 (12), 100895 (in press)
DOI 10.1016/j.modpat.2025.100895, PubMed 40998289

Publications 2024

Bischof K, Holth A, Bassarova A, Davidson B (2024)
Expression of PRAME in high-grade serous carcinoma is associated with higher residual disease volume and Occludin expression
266, 155787
DOI 10.1016/j.prp.2024.155787, PubMed 39709875

Casey NP, Kleinmanns K, Forcados C, Gelebart PF, Joaquina S, Lode M, Benard E, Kaveh F, Caulier B, Helgestad Gjerde C, García de Jalón E, Warren DJ, Lindemann K, Rokkones E, Davidson B, Myhre MR, Kvalheim G, Bjørge L, McCormack E, Inderberg EM, Wälchli S (2024)
Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16
12 (4)
DOI 10.1136/jitc-2023-008179, PubMed 38604812

Cun HT, Bernard L, Lande KT, Lawson BC, Nesbakken AJ, Davidson B, Lindemann K, Fellman B, Sørlie T, Soliman PT, Eriksson AGZ (2024)
Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma
189, 138-145
DOI 10.1016/j.ygyno.2024.07.677, PubMed 39126895

Davidson B, Holth A, Lindemann K, Zahl Eriksson AG, Nilsen TA, Torgunrud A (2024)
Molecular characteristics of tubo-ovarian carcinosarcoma at different anatomic locations
485 (6), 1053-1061
DOI 10.1007/s00428-024-03821-9, PubMed 38733380

Davidson B, Skeie-Jensen T, Holth A, Hausladen S (2024)
Stathmin is an Independent Prognostic Marker of Poor Outcome in Uterine Leiomyosarcoma
44 (1), 56-66
DOI 10.1097/PGP.0000000000001030, PubMed 38847524

Davidson B, Teien Lande K, Nebdal D, Nesbakken AJ, Holth A, Lindemann K, Zahl Eriksson AG, Sørlie T (2024)
Endometrial carcinomas with ambiguous histology often harbor TP53 mutations
486 (4), 697-705
DOI 10.1007/s00428-024-03912-7, PubMed 39235515

Sveen A, Johannessen B, Klokkerud SM, Kraggerud SM, Meza-Zepeda LA, Bjørnslett M, Bischof K, Myklebost O, Taskén K, Skotheim RI, Dørum A, Davidson B, Lothe RA (2024)
Evolutionary mode and timing of dissemination of high-grade serous carcinomas
9 (3)
DOI 10.1172/jci.insight.170423, PubMed 38175731

Publications 2023

Arjona-Sanchez A, Martinez-López A, Moreno-Montilla MT, Mulsow J, Lozano-Lominchar P, Martínez-Torres B, Rau B, Canbay E, Sommariva A, Milione M, Deraco M, Sgarbura O, Torgunrud A, Kepenekian V, Carr NJ, Hoorens A, Delhorme JB, Wernert R, Goere D, Martin-Roman L, Cosyns S, Flatmark K, Davidson B, Khellaf L, Pereira-Perez F et al. (2023)
External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification
49 (8), 1481-1488
DOI 10.1016/j.ejso.2023.03.206, PubMed 36935222

Davidson B, Doutel D, Holth A, Nymoen DA (2023)
Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma
482 (6), 975-982
DOI 10.1007/s00428-023-03541-6, PubMed 37067588

Davidson B, Skeie-Jensen T, Holth A, Lindemann K, Toralba Barrameda AM, Lie AK, Wang Y (2023)
Lymphovascular invasion and p16 expression are independent prognostic factors in stage I vulvar squamous cell carcinoma
484 (6), 951-963
DOI 10.1007/s00428-023-03670-y, PubMed 37843640

Dos Santos MV, Holth A, Bischof K, Davidson B (2023)
Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance
41 (1), 69-76
DOI 10.1007/s10585-023-10251-5, PubMed 38141113

Dos Santos MV, Holth A, Lindemann K, Staff AC, Davidson B (2023)
Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinoma
176, 76-81
DOI 10.1016/j.ygyno.2023.07.004, PubMed 37478615

Doutel D, Davidson B, Nitschke Pettersen IK, Torgunrud A (2023)
Molecular characteristics of low-grade serous carcinoma in effusions
34 (2), 99-105
DOI 10.1111/cyt.13207, PubMed 36609991

Gatius S, Matias Guiu X, Davidson B (2023)
Molecular features for timely cancer diagnosis and treatment - tumors of the ovary, fallopian tube and endometrium
484 (2), 339-351
DOI 10.1007/s00428-023-03710-7, PubMed 38099957

Panagopoulos I, Andersen K, Brunetti M, Gorunova L, Davidson B, Lund-Iversen M, Micci F, Heim S (2023)
Genetic Pathways in Peritoneal Mesothelioma Tumorigenesis
20 (4), 363-374
DOI 10.21873/cgp.20388, PubMed 37400148

Vermorgen S, Gelton T, Bult P, Kusters-Vandevelde HVN, Hausnerová J, Van de Vijver K, Davidson B, Stefansson IM, Kooreman LFS, Qerimi A, Huvila J, Gilks B, Shahi M, Zomer S, Bartosch C, Pijnenborg JMA, Bulten J, Ciompi F, Simons M (2023)
Endometrial Pipelle Biopsy Computer-Aided Diagnosis: A Feasibility Study
37 (2), 100417
DOI 10.1016/j.modpat.2023.100417, PubMed 38154654

Publications 2022

Brunetti M, Panagopoulos I, Vitelli V, Andersen K, Hveem TS, Davidson B, Eriksson AGZ, Trent PKB, Heim S, Micci F (2022)
Endometrial Carcinoma: Molecular Cytogenetics and Transcriptomic Profile
14 (14)
DOI 10.3390/cancers14143536, PubMed 35884597

Davidson B, Elstrand MB (2022)
Clinicopathological prognostic parameters in patients with tubo-ovarian carcinoma effusions
33 (4), 479-492
DOI 10.1111/cyt.13126, PubMed 35398934

Gatius S, Velasco A, Varela M, Cuatrecasas M, Jares P, Setaffy L, Bonhomme B, Santon A, Lindemann K, Croce S, Davidson B, Lax S, Palacios J, Matias-Guiu X (2022)
Comparison of the Idylla™ MSI assay with the Promega™ MSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study
480 (5), 1031-1039
DOI 10.1007/s00428-022-03291-x, PubMed 35124717

Kleinmanns K, Gullaksen SE, Bredholt G, Davidson B, Torkildsen CF, Grindheim S, Bjørge L, McCormack E (2022)
Humanized Ovarian Cancer Patient-Derived Xenografts for Improved Preclinical Evaluation of Immunotherapies
14 (13)
DOI 10.3390/cancers14133092, PubMed 35804867

Onallah H, Mannully ST, Davidson B, Reich R (2022)
Exosome Secretion and Epithelial-Mesenchymal Transition in Ovarian Cancer Are Regulated by Phospholipase D
23 (21)
DOI 10.3390/ijms232113286, PubMed 36362078

Panagopoulos I, Andersen K, Gorunova L, Davidson B, Micci F, Heim S (2022)
A Novel Cryptic t(2;3)(p21;q25) Translocation Fuses the WWTR1 and PRKCE Genes in Uterine Leiomyoma With 3q- as the Sole Visible Chromosome Abnormality
19 (5), 636-646
DOI 10.21873/cgp.20348, PubMed 35985686

Panagopoulos I, Andersen K, Gorunova L, Davidson B, Micci F, Heim S (2022)
Fusion of the HMGA2 and BNC2 Genes in Uterine Leiomyoma With t(9;12)(p22;q14)
36 (6), 2654-2661
DOI 10.21873/invivo.13000, PubMed 36309352

Sonzini G, Granados-Aparici S, Sanegre S, Diaz-Lagares A, Diaz-Martin J, de Andrea C, Eritja N, Bao-Caamano A, Costa-Fraga N, García-Ros D, Salguero-Aranda C, Davidson B, López-López R, Melero I, Navarro S, Ramon Y Cajal S, de Alava E, Matias-Guiu X, Noguera R (2022)
Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness
10, 1052098
DOI 10.3389/fcell.2022.1052098, PubMed 36467415

Van Nyen T, Planque M, van Wagensveld L, Duarte JAG, Zaal EA, Talebi A, Rossi M, Körner PR, Rizzotto L, Moens S, De Wispelaere W, Baiden-Amissah REM, Sonke GS, Horlings HM, Eelen G, Berardi E, Swinnen JV, Berkers CR, Carmeliet P, Lambrechts D, Davidson B, Agami R, Fendt SM, Annibali D, Amant F (2022)
Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers
13 (1), 4578
DOI 10.1038/s41467-022-32272-6, PubMed 35931688

Publications 2021

Andersson Y, Fleten KG, Abrahamsen TW, Reed W, Davidson B, Flatmark K (2021)
Anti-Angiogenic Treatment in Pseudomyxoma Peritonei-Still a Strong Preclinical Rationale
Cancers, 13 (11), 2819
DOI 10.3390/cancers13112819

Davidson B, Kleinberg L, Børresen IM, Slettevoll F, Fangberget A, Hindosh D, Zahl Eriksson AG, Bjerkehagen B (2021)
Primary uterine ectomesenchymoma harboring a DICER1 mutation: case report with molecular analysis
479 (2), 419-424
DOI 10.1007/s00428-021-03057-x, PubMed 33595736

de Garibay GR, Jalon EGD, Stigen E, Lund KB, Popa M, Davidson B, Safont MM, Rygh CB, Espedal H, Barrett TM, Haug BE, McCormack E (2021)
Repurposing F-18-FMISO as a PET tracer for translational imaging of nitroreductase-based gene directed enzyme prodrug therapy
Theranostics, 11 (12), 6044-6057
DOI 10.7150/thno.55092

Eriksson AGZ, Davidson B, Bjerre Trent P, Eyjólfsdóttir B, Dahl GF, Wang Y, Staff AC (2021)
Update on Sentinel Lymph Node Biopsy in Surgical Staging of Endometrial Carcinoma
10 (14)
DOI 10.3390/jcm10143094, PubMed 34300260

Flatmark K, Torgunrud A, Fleten KG, Davidson B, Juul HV, Mensali N, Lund-Andersen C, Inderberg EM (2021)
Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei
9 (10)
DOI 10.1136/jitc-2021-003109, PubMed 34711663

García de Jalón E, Kleinmanns K, Fosse V, Davidson B, Bjørge L, Haug BE, McCormack E (2021)
Comparison of Five Near-Infrared Fluorescent Folate Conjugates in an Ovarian Cancer Model
25 (1), 144-155
DOI 10.1007/s11307-021-01685-y, PubMed 34888759

Jacobs Catane L, Moshel O, Smith Y, Davidson B, Reich R (2021)
Splice-Variant Knock-Out of TGFβ Receptors Perturbates the Proteome of Ovarian Carcinoma Cells
22 (23)
DOI 10.3390/ijms222312647, PubMed 34884451

Sanegre S, Eritja N, de Andrea C, Diaz-Martin J, Diaz-Lagares A, Jacome MA, Salguero-Aranda C, Ros DG, Davidson B, Lopez R, Melero I, Navarro S, Cajal SRY, de Alava E, Matias-Guiu X, Noguera R (2021)
Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma
Front. Cell. Dev. Biol., 9, 670185
DOI 10.3389/fcell.2021.670185

Publications 2020

Broner EC, Onallah H, Re'em TT, Davidson B, Reich R (2020)
Role of the Exosome Secretion Machinery in Ovarian Carcinoma: In Vitro and In Vivo Models
J. Oncol., 2020, 4291827
DOI 10.1155/2020/4291827

Brunetti M, Panagopoulos I, Kostolomov I, Davidson B, Heim S, Micci F (2020)
Mutation analysis and genomic imbalances of cells found in effusion fluids from patients with ovarian cancer
20 (3), 2273-2279
DOI 10.3892/ol.2020.11782, PubMed 32782545

Chehover M, Reich R, Davidson B (2020)
Expression of Wnt pathway molecules is associated with disease outcome in metastatic high-grade serous carcinoma
477 (2), 249-258
DOI 10.1007/s00428-019-02737-z, PubMed 31900634

Davidson B (2020)
Molecular testing on serous effusions
49 (5), 640-646
DOI 10.1002/dc.24392, PubMed 32023012

Davidson B, Bock AJ, Holth A, Nymoen DA (2020)
Expression of palladin is associated with disease progression in metastatic high-grade serous carcinoma
31 (6), 572-578
DOI 10.1111/cyt.12895, PubMed 32741023

Davidson B, Bock AJ, Holth A, Nymoen DA (2020)
The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma
32 (2), 161-168
DOI 10.1111/cyt.12921, PubMed 33025675

Davidson B, Holth A, Dong HP (2020)
Expression of the cancer stem cell marker SSEA1 is associated with poor survival in metastatic high-grade serous carcinoma
477 (5), 677-685
DOI 10.1007/s00428-020-02850-4, PubMed 32472195

Davidson B, Matias-Guiu X, Lax SF (2020)
The clinical, morphological, and genetic heterogeneity of endometrial stromal sarcoma
476 (4), 489-490
DOI 10.1007/s00428-020-02762-3, PubMed 31993772

Davidson B, McFadden E, Holth A, Brunetti M, Flørenes VA (2020)
Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma
477 (6), 857-864
DOI 10.1007/s00428-020-02842-4, PubMed 32533344

Filippov-Levy N, Davidson B, Reich R (2020)
The Biological Role of the Long Non-coding RNA LINK-A in Ovarian Carcinoma
40 (12), 6677-6684
DOI 10.21873/anticanres.14691, PubMed 33288561

Filippov-Levy N, Reich R, Davidson B (2020)
The Biological and Clinical Role of the Long Non-Coding RNA LOC642852 in Ovarian Carcinoma
21 (15)
DOI 10.3390/ijms21155237, PubMed 32718068

Kleinmanns K, Fosse V, Davidson B, de Jalón EG, Tenstad O, Bjørge L, McCormack E (2020)
CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model
56, 102783
DOI 10.1016/j.ebiom.2020.102783, PubMed 32454402

Schenck A, Vera-Rodriguez M, Greggains G, Davidson B, Fedorcsák P (2020)
Spatial and temporal changes in follicle distribution in the human ovarian cortex
42 (2), 375-383
DOI 10.1016/j.rbmo.2020.10.013, PubMed 33309389

Sharma A, Davidson B, Skeie-Jensen T, Wang Y (2020)
Fifteen Years’ Experience with Vulvar Verrucous Carcinoma at a Single Norwegian Academic Cancer Center
Journal of Gynecology and Women Healthcare, 2 (2), 1-4
PublikaID 489

Shen YA, Hong J, Asaka R, Asaka S, Hsu FC, Suryo Rahmanto Y, Jung JG, Chen YW, Yen TT, Tomaszewski A, Zhang C, Attarwala N, DeMarzo AM, Davidson B, Chuang CM, Chen X, Gaillard S, Le A, Shih IM, Wang TL (2020)
Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers
80 (20), 4514-4526
DOI 10.1158/0008-5472.CAN-19-3971, PubMed 32859605

Publications 2019

Binzer-Panchal A, Hardell E, Viklund B, Ghaderi M, Bosse T, Nucci MR, Lee CH, Hollfelder N, Corcoran P, Gonzalez-Molina J, Moyano-Galceran L, Bell DA, Schoolmeester JK, Måsbäck A, Kristensen GB, Davidson B, Lehti K, Isaksson A, Carlson JW (2019)
Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes
25 (7), 2155-2165
DOI 10.1158/1078-0432.CCR-18-2792, PubMed 30617134

Brunetti M, Agostini A, Staurseth J, Davidson B, Heim S, Micci F (2019)
Molecular characterization of carcinosarcomas arising in the uterus and ovaries
10 (38), 3614-3624
DOI 10.18632/oncotarget.26942, PubMed 31217897

Brunetti M, Panagopoulos I, Micci F, Davidson B (2019)
MGMT promoter methylation is a rare epigenetic change in malignant effusions
31 (1), 12-15
DOI 10.1111/cyt.12782, PubMed 31808217

Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, Baert T, Belaroussi I, Dashora A, Olbrecht S, Planchamp F, Querleu D, Baert T, Banerjee S, Belaroussi I, Blecharz P, Bruchim I, Cibula D, Colombo N, Concin N, Davidson B et al. (2019)
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Ann. Oncol., 30 (5), 672-705
DOI 10.1093/annonc/mdz062

Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, Baert T, Belaroussi I, Dashora A, Olbrecht S, Planchamp F, Querleu D, Banerjee S, Blecharz P, Bruchim I, Cibula D, Concin N, Davidson B, Devouassoux-Shisheboran M, Ferrero A, Glasspool R et al. (2019)
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Int. J. Gynecol. Cancer, 29 (4), 728-760
DOI 10.1136/ijgc-2019-000308

Davidson B (2019)
Biomarkers of drug resistance in ovarian cancer - an update
19 (6), 469-476
DOI 10.1080/14737159.2019.1618187, PubMed 31075061

Dominguez-Valentin M, Nakken S, Tubeuf H, Vodak D, Ekstrøm PO, Nissen AM, Morak M, Holinski-Feder E, Holth A, Capella G, Davidson B, Evans DG, Martins A, Møller P, Hovig E (2019)
Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing
9 (1), 18555
DOI 10.1038/s41598-019-54517-z, PubMed 31811167

Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Julsrud L, Fodstad Ø, Dueland S, Flatmark K (2019)
ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis
47 (1), 134-138
DOI 10.1016/j.ejso.2019.04.014, PubMed 31036394

Lund-Andersen C, Nakken S, Nygård S, Fromm B, Aasheim LB, Davidson B, Julsrud L, Abrahamsen TW, Kristensen AT, Dybdahl B, Larsen SG, Hovig E, Flatmark K (2019)
Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response
5 (2)
DOI 10.1101/mcs.a003566, PubMed 30862609

Murali R, Davidson B, Fadare O, Carlson JA, Crum CP, Gilks CB, Irving JA, Malpica A, Matias-Guiu X, McCluggage WG, Mittal K, Oliva E, Parkash V, Rutgers JKL, Staats PN, Stewart CJR, Tornos C, Soslow RA (2019)
High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations
38 Suppl 1 (Iss 1 Suppl 1), S40-S63
DOI 10.1097/PGP.0000000000000491, PubMed 30550483

Onallah H, Davidson B, Reich R (2019)
Diverse Effects of Lysophosphatidic Acid Receptors on Ovarian Cancer Signaling Pathways
2019, 7547469
DOI 10.1155/2019/7547469, PubMed 31636669

Sherman-Samis M, Onallah H, Holth A, Reich R, Davidson B (2019)
SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma
153 (3), 651-660
DOI 10.1016/j.ygyno.2019.03.099, PubMed 30904337

Wohlschlaeger J, Davidson B, Worm K, Feist H, Peters J, Hager T, Schmid KW, Ostertag H (2019)
Papilloma of the Fallopian Tube: A Rare Gynecologic Neoplasm Harboring a BRAF (c.1799T>A) Mutation (V600E)
38 (5), 459-463
DOI 10.1097/PGP.0000000000000526, PubMed 29851866

Yu Y, Suryo Rahmanto Y, Shen YA, Ardighieri L, Davidson B, Gaillard S, Ayhan A, Shi X, Xuan J, Wang TL, Shih IM (2019)
Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer
47, 184-194
DOI 10.1016/j.ebiom.2019.08.055, PubMed 31492560

Publications 2018

Agostini A, Brunetti M, Davidson B, Göran Tropé C, Heim S, Panagopoulos I, Micci F (2018)
Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas
143 (6), 1379-1387
DOI 10.1002/ijc.31418, PubMed 29633253

Agostini A, Brunetti M, Davidson B, Tropé CG, Eriksson AGZ, Heim S, Panagopoulos I, Micci F (2018)
The microRNA miR-192/215 family is upregulated in mucinous ovarian carcinomas
8 (1), 11069
DOI 10.1038/s41598-018-29332-7, PubMed 30038317

Brunetti M, Gorunova L, Davidson B, Heim S, Panagopoulos I, Micci F (2018)
Identification of an EPC2-PHF1 fusion transcript in low-grade endometrial stromal sarcoma
9 (27), 19203-19208
DOI 10.18632/oncotarget.24969, PubMed 29721194

Brunetti M, Holth A, Panagopoulos I, Staff AC, Micci F, Davidson B (2018)
Expression and clinical role of the dipeptidyl peptidases DPP8 and DPP9 in ovarian carcinoma
474 (2), 177-185
DOI 10.1007/s00428-018-2487-x, PubMed 30467600

Davidson B (2018)
Circulating tumor cells and cell-free nucleic acids in patients with gynecological malignancies
473 (4), 395-403
DOI 10.1007/s00428-018-2447-5, PubMed 30145616

Davidson B, Bjørnerem M, Holth A, Hellesylt E, Hetland Falkenthal TE, Flørenes VA (2018)
Expression, activation and clinical relevance of CHK1 and CHK2 in metastatic high-grade serous carcinoma
150 (1), 136-142
DOI 10.1016/j.ygyno.2018.05.007, PubMed 29804637

Davidson B, Holth A, Wang Z, Hellsylt E, Tropé CG, Hetland Falkenthal TE, Holm R (2018)
Expression of 14-3-3 sigma and eta proteins is unrelated to survival in metastatic high-grade serous carcinoma
126 (4), 309-313
DOI 10.1111/apm.12816, PubMed 29464778

Davidson B, Tötsch M, Wohlschlaeger J, Hager T, Pinamonti M (2018)
The diagnostic role of BAP1 in serous effusions
79, 122-126
DOI 10.1016/j.humpath.2018.05.012, PubMed 29802871

Filippov-Levy N, Cohen-Schussheim H, Tropé CG, Hetland Falkenthal TE, Smith Y, Davidson B, Reich R (2018)
Expression and clinical role of long non-coding RNA in high-grade serous carcinoma
148 (3), 559-566
DOI 10.1016/j.ygyno.2018.01.004, PubMed 29310950

Flem Karlsen K, McFadden E, Flørenes VA, Davidson B (2018)
Soluble AXL is ubiquitously present in malignant serous effusions
152 (2), 408-415
DOI 10.1016/j.ygyno.2018.11.012, PubMed 30448261

Lønning PE, Berge EO, Bjørnslett M, Minsaas L, Chrisanthar R, Høberg-Vetti H, Dulary C, Busato F, Bjørneklett S, Eriksen C, Kopperud R, Axcrona U, Davidson B, Bjørge L, Evans G, Howell A, Salvesen HB, Janszky I, Hveem K, Romundstad PR, Vatten LJ, Tost J, Dørum A, Knappskog S (2018)
White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk
168 (5), 326-334
DOI 10.7326/M17-0101, PubMed 29335712

Matias-Guiu X, Davidson B, Lax SF (2018)
Can the classification of low-grade endometrial stromal tumors still be improved?
473 (6), 663-664
DOI 10.1007/s00428-018-2474-2, PubMed 30367239

Onallah H, Catane LJ, Tropé CG, Hetland Falkenthal TE, Reich R, Davidson B (2018)
Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma
473 (4), 463-470
DOI 10.1007/s00428-018-2418-x, PubMed 30032361

Smogeli E, Cvancarova M, Wang Y, Davidson B, Kristensen G, Lindemann K (2018)
Clinical Outcome of Patients With High-Risk Endometrial Carcinoma After Treatment With Chemotherapy Only
28 (9), 1789-1795
DOI 10.1097/IGC.0000000000001356, PubMed 30365455

Publications 2017

Agostini A, Brunetti M, Davidson B, Tropé CG, Heim S, Panagopoulos I, Micci F (2017)
Genomic imbalances are involved in miR-30c and let-7a deregulation in ovarian tumors: implications for HMGA2 expression
8 (13), 21554-21560
DOI 10.18632/oncotarget.15795, PubMed 28423547

Andersson Y, Haavardtun SI, Davidson B, Dorum A, Fleten KG, Fodstad O, Flatmark K (2017)
MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer
Oncotarget, 8 (37), 61800-61809
DOI 10.18632/oncotarget.18694

Brunetti M, Agostini A, Davidson B, Tropé CG, Heim S, Panagopoulos I, Micci F (2017)
Recurrent fusion transcripts in squamous cell carcinomas of the vulva
8 (10), 16843-16850
DOI 10.18632/oncotarget.15167, PubMed 28186972

Brunetti M, Panagopoulos I, Gorunova L, Davidson B, Heim S, Micci F (2017)
RNA-sequencing identifies novel GREB1-NCOA2 fusion gene in a uterine sarcoma with the chromosomal translocation t(2;8)(p25;q13)
57 (4), 176-181
DOI 10.1002/gcc.22518, PubMed 29218853

Davidson B, Hellesylt E, Holth A, Danielsen HE, Skeie-Jensen T, Katz B (2017)
Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma
471 (3), 355-362
DOI 10.1007/s00428-017-2172-5, PubMed 28643014

Davidson B, Micci F (2017)
Molecular characteristics of uterine sarcomas
Expert Rev. Mol. Diagn., 17 (5), 515-522
DOI 10.1080/14737159.2017.1311790

Davidson B, Pinamonti M, Cuevas D, Holth A, Zeppa P, Hager T, Wohlschlaeger J, Tötsch M (2017)
The diagnostic role of PTEN and ARID1A in serous effusions
472 (3), 425-432
DOI 10.1007/s00428-017-2273-1, PubMed 29170871

Froysnes IS, Andersson Y, Larsen SG, Davidson B, Oien JMT, Olsen KH, Giercksky KE, Julsrud L, Fodstad O, Dueland S, Flatmark K (2017)
Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial
Ann. Surg. Oncol., 24 (7), 1916-1922
DOI 10.1245/s10434-017-5814-6

Gutgold N, Davidson B, Catane LJ, Holth A, Hellesylt E, Trope CG, Dorum A, Reich R (2017)
TGF beta splicing and canonical pathway activation in high-grade serous carcinoma
Virchows Arch., 470 (6), 665-678
DOI 10.1007/s00428-017-2127-x

Hardell E, Josefson S, Ghaderi M, Skeie-Jensen T, Westbom-Fremer S, Cheek EH, Bell D, Selling J, Schoolmeester JK, Måsbäck A, Davidson B, Carlson JW (2017)
Validation of a Mitotic Index Cutoff as a Prognostic Marker in Undifferentiated Uterine Sarcomas
41 (9), 1231-1237
DOI 10.1097/PAS.0000000000000894, PubMed 28622181

Harel-Dassa K, Yedgar S, Trope CG, Davidson B, Reich R (2017)
Phospholipase D messenger RNA expression and clinical role in high-grade serous carcinoma
Hum. Pathol., 62, 115-121
DOI 10.1016/j.humpath.2016.12.023

Lewis N, Soslow RA, Delair DF, Park KJ, Murali R, Hollmann TJ, Davidson B, Micci F, Panagopoulos I, Hoang LN, Arias-Stella JA, Oliva E, Young RH, Hensley ML, Leitao MM, Hameed M, Benayed R, Ladanyi M, Frosina D, Jungbluth AA, Antonescu CR, Chiang S (2017)
ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity
31 (4), 674-684
DOI 10.1038/modpathol.2017.162, PubMed 29192652

Nastic D, Shanwell E, Wallin KL, Valla M, Masback A, Mateoiu C, Lidang M, Liakka A, Lappi-Blanco E, Grove A, Davidson B, Carpen O, Bertelsen BI, Bak J, Abusland AB, Selling J, Carlson JW (2017)
A Selective Biomarker Panel Increases the Reproducibility and the Accuracy in Endometrial Biopsy Diagnosis
Int. J. Gynecol. Pathol., 36 (4), 339-347
DOI 10.1097/PGP.0000000000000334

Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, Aletti G, Carinelli S, Creutzberg C, Davidson B, Harter P, Lundvall L, Marth C, Morice P, Rafii A, Ray-Coquard I, Rockall A, Sessa C, van der Zee A, Vergote I, duBois A (2017)
European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery
Int. J. Gynecol. Cancer, 27 (7), 1534-1542
DOI 10.1097/IGC.0000000000001041

Smebye ML, Agostini A, Johannessen B, Thorsen J, Davidson B, Tropé CG, Heim S, Skotheim RI, Micci F (2017)
Involvement of DPP9 in gene fusions in serous ovarian carcinoma
17 (1), 642
DOI 10.1186/s12885-017-3625-6, PubMed 28893231

Solheim O, Førsund M, Tropé CG, Kraggerud SM, Nesland JM, Davidson B (2017)
Epithelial-mesenchymal transition markers in malignant ovarian germ cell tumors
125 (9), 781-786
DOI 10.1111/apm.12715, PubMed 28585395

Publications 2016

Agostini A, Brunetti M, Davidson B, Trope CG, Heim S, Panagopoulos I, Micci F (2016)
Expressions of miR-30c and let-7a are inversely correlated with HMGA2 expression in squamous cell carcinoma of the vulva
7 (51), 85058-85062
DOI 10.18632/oncotarget.13187, PubMed 27835588

Agostini A, Panagopoulos I, Davidson B, Trope CG, Heim S, Micci F (2016)
A novel truncated form of HMGA2 in tumors of the ovaries
12 (2), 1559-1563
DOI 10.3892/ol.2016.4805, PubMed 27446471

Broner EC, Tropé CG, Reich R, Davidson B (2016)
TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma
60, 180-187
DOI 10.1016/j.humpath.2016.10.017, PubMed 27825812

Davidson B (2016)
Recently identified drug resistance biomarkers in ovarian cancer
16 (5), 569-78
DOI 10.1586/14737159.2016.1156532, PubMed 26895188

Davidson B (2016)
Malignant Nonhematological Effusion Characterization by Flow Cytometry
60 (4), 365-371
DOI 10.1159/000447687, PubMed 27532128

Davidson B (2016)
CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells
58, 123-127
DOI 10.1016/j.humpath.2016.08.005, PubMed 27589896

Davidson B, Kjæreng ML, Førsund M, Danielsen HE, Kristensen GB, Abeler VM (2016)
Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma
145 (4), 449-58
DOI 10.1093/ajcp/aqw030, PubMed 27149024

Davidson B, Valborg Reinertsen K, Trinh D, Reed W, Bøhler PJ (2016)
BAG-1/SODD, HSP70, and HSP90 are potential prognostic markers of poor survival in node-negative breast carcinoma
54, 64-73
DOI 10.1016/j.humpath.2016.02.023, PubMed 27038683

Horwitz V, Davidson B, Stern D, Tropé CG, Tavor Re'em T, Reich R (2016)
Ezrin Is Associated with Disease Progression in Ovarian Carcinoma
11 (9), e0162502
DOI 10.1371/journal.pone.0162502, PubMed 27622508

Jung JG, Shih IM, Park JT, Gerry E, Kim TH, Ayhan A, Handschuh K, Davidson B, Fader AN, Selleri L, Wang TL (2016)
Ovarian Cancer Chemoresistance Relies on the Stem Cell Reprogramming Factor PBX1
76 (21), 6351-6361
DOI 10.1158/0008-5472.CAN-16-0980, PubMed 27590741

Lee JC, Lu TP, Changou CA, Liang CW, Huang HN, Lauria A, Huang HY, Lin CY, Chiang YC, Davidson B, Lin MC, Kuo KT (2016)
Genomewide copy number analysis of Müllerian adenosarcoma identified chromosomal instability in the aggressive subgroup
29 (9), 1070-82
DOI 10.1038/modpathol.2016.99, PubMed 27255164

Lehtinen L, Vesterkvist P, Roering P, Korpela T, Hattara L, Kaipio K, Mpindi JP, Hynninen J, Auranen A, Davidson B, Haglund C, Iljin K, Grenman S, Siitari H, Carpen O (2016)
REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker
11 (3), e0151590
DOI 10.1371/journal.pone.0151590, PubMed 26981633

Micci F, Gorunova L, Agostini A, Johannessen LE, Brunetti M, Davidson B, Heim S, Panagopoulos I (2016)
Cytogenetic and molecular profile of endometrial stromal sarcoma
55 (11), 834-46
DOI 10.1002/gcc.22380, PubMed 27219024

Michael CW, Davidson B (2016)
Pre-analytical issues in effusion cytology
Pleura Peritoneum, 1 (1), 45-56
DOI 10.1515/pap-2016-0001

Nymoen DA, Slipicevic A, Holth A, Emilsen E, Hetland Falkenthal TE, Tropé CG, Reich R, Flørenes VA, Davidson B (2016)
MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma
54, 74-81
DOI 10.1016/j.humpath.2016.03.010, PubMed 27063471

Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, Aletti G, Carinelli S, Creutzberg C, Davidson B, Harter P, Lundvall L, Marth C, Morice P, Rafii A, Ray-Coquard I, Rockall A, Sessa C, van der Zee A, Vergote I, du Bois A (2016)
European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery
Int. J. Gynecol. Cancer, 26 (7), 1354-1363
DOI 10.1097/IGC.0000000000000767

Ravid Y, Formanski M, Smith Y, Reich R, Davidson B (2016)
Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures
140 (3), 512-7
DOI 10.1016/j.ygyno.2016.01.001, PubMed 26768834

Smebye ML, Haugom L, Davidson B, Trope CG, Heim S, Skotheim RI, Micci F (2016)
Bilateral ovarian carcinomas differ in the expression of metastasis-related genes
13 (1), 184-190
DOI 10.3892/ol.2016.5384, PubMed 28123539

Smogeli E, Davidson B, Cvancarova M, Holth A, Katz B, Risberg B, Kristensen G, Lindemann K (2016)
L1CAM as a prognostic marker in stage I endometrial cancer: a validation study
16, 596
DOI 10.1186/s12885-016-2631-4, PubMed 27488577

Tambe M, Pruikkonen S, Mäki-Jouppila J, Chen P, Elgaaen BV, Straume AH, Huhtinen K, Cárpen O, Lønning PE, Davidson B, Hautaniemi S, Kallio MJ (2016)
Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel
7 (11), 12267-85
DOI 10.18632/oncotarget.7860, PubMed 26943585

van der Putten LJ, van de Vijver K, Bartosch C, Davidson B, Gatius S, Matias-Guiu X, McCluggage WG, Toledo G, van der Wurff AA, Pijnenborg JM, Massuger LF, Bulten J (2016)
Reproducibility of measurement of myometrial invasion in endometrial carcinoma
470 (1), 63-68
DOI 10.1007/s00428-016-2035-5, PubMed 27787595

Publications 2015

Agostini A, Panagopoulos I, Andersen HK, Johannesen LE, Davidson B, Tropé CG, Heim S, Micci F (2015)
HMGA2 expression pattern and TERT mutations in tumors of the vulva
33 (6), 2675-80
DOI 10.3892/or.2015.3882, PubMed 25823555

Bartlett TE, Jones A, Goode EL, Fridley BL, Cunningham JM, Berns EM, Wik E, Salvesen HB, Davidson B, Trope CG, Lambrechts S, Vergote I, Widschwendter M (2015)
Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers
10 (12), e0143178
DOI 10.1371/journal.pone.0143178, PubMed 26629914

Davidson B (2015)
Prognostic factors in malignant pleural mesothelioma
46 (6), 789-804
DOI 10.1016/j.humpath.2015.02.006, PubMed 25824607

Davidson B, Holth A, Hellesylt E, Hadar R, Katz B, Tropé CG, Reich R (2015)
HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival
48, 95-101
DOI 10.1016/j.humpath.2015.09.027, PubMed 26640230

Davidson B, Stavnes HT, Hellesylt E, Hager T, Zeppa P, Pinamonti M, Wohlschlaeger J (2015)
MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions
47 (1), 104-8
DOI 10.1016/j.humpath.2015.08.020, PubMed 26520416

Hjerpe A, Ascoli V, Bedrossian C, Boon M, Creaney J, Davidson B, Dejmek A, Dobra K, Fassina A, Field A, Firat P, Kamei T, Kobayashi T, Michael CW, Önder S, Segal A, Vielh P (2015)
Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology
12, 26
DOI 10.4103/1742-6413.170726, PubMed 26681974

Hjerpe A, Ascoli V, Bedrossian CW, Boon ME, Creaney J, Davidson B, Dejmek A, Dobra K, Fassina A, Field A, Firat P, Kamei T, Kobayashi T, Michael CW, Önder S, Segal A, Vielh P (2015)
Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: a secondary publication
26 (3), 142-56
DOI 10.1111/cyt.12250, PubMed 26052757

Hjerpe A, Ascoli V, Bedrossian CW, Boon ME, Creaney J, Davidson B, Dejmek A, Dobra K, Fassina A, Field A, Firat P, Kamei T, Kobayashi T, Michael CW, Önder S, Segal A, Vielh P, International Mesothelioma Interest Group, International Academy of Cytology (2015)
Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology
43 (7), 563-76
DOI 10.1002/dc.23271, PubMed 26100969

Hjerpe A, Ascoli V, Bedrossian CWM, Boon ME, Creaney J, Davidson B, Dejmek A, Dobra K, Fassina A, Field A, Firat P, Kamei T, Kobayashi T, Michael CW, Onder S, Segal A, Vielh P (2015)
Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma
Acta Cytol., 59 (1), 2-16
DOI 10.1159/000377697

Howell VM, Davidson B (2015)
Editorial: Advances in Epithelial Ovarian Cancer: Model Systems, Microenvironmental Influences, Therapy, and Origins
5, 205
DOI 10.3389/fonc.2015.00205, PubMed 26442217

Jakobsson ME, Moen A, Davidson B, Falnes PØ (2015)
Hsp70 (HSPA1) Lysine Methylation Status as a Potential Prognostic Factor in Metastatic High-Grade Serous Carcinoma
10 (10), e0140168
DOI 10.1371/journal.pone.0140168, PubMed 26448330

Katz B, Tropé CG, Reich R, Davidson B (2015)
MicroRNAs in Ovarian Cancer
46 (9), 1245-56
DOI 10.1016/j.humpath.2015.06.013, PubMed 26216350

Kolberg M, Høland M, Lind GE, Ågesen TH, Skotheim RI, Hall KS, Mandahl N, Smeland S, Mertens F, Davidson B, Lothe RA (2015)
Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours--A prognostic test after surgical resection
9 (6), 1129-39
DOI 10.1016/j.molonc.2015.02.005, PubMed 25769404

McCluggage WG, Judge MJ, Clarke BA, Davidson B, Gilks CB, Hollema H, Ledermann JA, Matias-Guiu X, Mikami Y, Stewart CJ, Vang R, Hirschowitz L, International Collaboration on Cancer Reporting (2015)
Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)
28 (8), 1101-22
DOI 10.1038/modpathol.2015.77, PubMed 26089092

Nymoen DA, Hetland Falkenthal TE, Holth A, Ow GS, Ivshina AV, Tropé CG, Kuznetsov VA, Staff AC, Davidson B (2015)
Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma
139 (1), 30-9
DOI 10.1016/j.ygyno.2015.07.107, PubMed 26232338

Nymoen DA, Holth A, Hetland Falkenthal TE, Tropé CG, Davidson B (2015)
CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma
14, 44
DOI 10.1186/s12943-015-0317-1, PubMed 25889687

Teschendorff AE, Lee SH, Jones A, Fiegl H, Kalwa M, Wagner W, Chindera K, Evans I, Dubeau L, Orjalo A, Horlings HM, Niederreiter L, Kaser A, Yang W, Goode EL, Fridley BL, Jenner RG, Berns EM, Wik E, Salvesen HB, Wisman GB, van der Zee AG, Davidson B, Trope CG, Lambrechts S et al. (2015)
HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer
7, 108
DOI 10.1186/s13073-015-0233-4, PubMed 26497652

Yu Y, Gaillard S, Phillip JM, Huang TC, Pinto SM, Tessarollo NG, Zhang Z, Pandey A, Wirtz D, Ayhan A, Davidson B, Wang TL, Shih IeM (2015)
Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules
28 (1), 82-96
DOI 10.1016/j.ccell.2015.05.009, PubMed 26096845

Publications 2014

Davidson B, Holth A, Hellesylt E, Tan TZ, Huang RY, Tropé C, Nesland JM, Thiery JP (2014)
The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions
46 (1), 1-8
DOI 10.1016/j.humpath.2014.10.004, PubMed 25455994

Davidson B, Nymoen DA, Elgaaen BV, Staff AC, Tropé CG, Kærn J, Reich R, Falkenthal TE (2014)
BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma
464 (6), 701-7
DOI 10.1007/s00428-014-1577-7, PubMed 24756216

Davidson B, Rosenfeld YB, Holth A, Hellesylt E, Tropé CG, Reich R, Yisraeli JK (2014)
VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival
45 (7), 1520-8
DOI 10.1016/j.humpath.2014.03.005, PubMed 24814803

Davidson B, Tropé CG (2014)
Ovarian cancer: diagnostic, biological and prognostic aspects
10 (5), 519-33
DOI 10.2217/whe.14.37, PubMed 25335543

Davidson B, Tropé CG, Reich R (2014)
The clinical and diagnostic role of microRNAs in ovarian carcinoma
133 (3), 640-6
DOI 10.1016/j.ygyno.2014.03.575, PubMed 24713546

Davidson B, Trope CG, Reich R (2014)
The role of the tumor stroma in ovarian cancer
4, 104
DOI 10.3389/fonc.2014.00104, PubMed 24860785

Maimon A, Mogilevsky M, Shilo A, Golan-Gerstl R, Obiedat A, Ben-Hur V, Lebenthal-Loinger I, Stein I, Reich R, Beenstock J, Zehorai E, Andersen CL, Thorsen K, Ørntoft TF, Davis RJ, Davidson B, Mu D, Karni R (2014)
Mnk2 alternative splicing modulates the p38-MAPK pathway and impacts Ras-induced transformation
7 (2), 501-513
DOI 10.1016/j.celrep.2014.03.041, PubMed 24726367

Matias-Guiu X, Davidson B (2014)
Prognostic biomarkers in endometrial and ovarian carcinoma
Virchows Arch., 464 (3), 315-331
DOI 10.1007/s00428-013-1509-y

Micci F, Gorunova L, Gatius S, Matias-Guiu X, Davidson B, Heim S, Panagopoulos I (2014)
MEAF6/PHF1 is a recurrent gene fusion in endometrial stromal sarcoma
347 (1), 75-8
DOI 10.1016/j.canlet.2014.01.030, PubMed 24530230

Micci F, Haugom L, Abeler VM, Davidson B, Tropé CG, Heim S (2014)
Genomic profile of ovarian carcinomas
14, 315
DOI 10.1186/1471-2407-14-315, PubMed 24886194

Micci F, Panagopoulos I, Thorsen J, Davidson B, Tropé CG, Heim S (2014)
Low frequency of ESRRA-C11orf20 fusion gene in ovarian carcinomas
12 (2), e1001784
DOI 10.1371/journal.pbio.1001784, PubMed 24504521

Panagopoulos I, Gorunova L, Davidson B, Heim S (2014)
Novel TNS3-MAP3K3 and ZFPM2-ELF5 fusion genes identified by RNA sequencing in multicystic mesothelioma with t(7;17)(p12;q23) and t(8;11)(q23;p13)
357 (2), 502-9
DOI 10.1016/j.canlet.2014.12.002, PubMed 25484136

Slipicevic A, Holth A, Hellesylt E, Tropé CG, Davidson B, Flørenes VA (2014)
Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions
135 (1), 118-24
DOI 10.1016/j.ygyno.2014.07.102, PubMed 25093290

Smebye ML, Sveen A, Haugom L, Davidson B, Tropé CG, Lothe RA, Heim S, Skotheim RI, Micci F (2014)
Chromosome 19 rearrangements in ovarian carcinomas: zinc finger genes are particularly targeted
53 (7), 558-67
DOI 10.1002/gcc.22166, PubMed 24634323

Tuft Stavnes H, Nymoen DA, Hetland Falkenthal TE, Kærn J, Tropé CG, Davidson B (2014)
APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival
142 (1), 51-7
DOI 10.1309/AJCPD8NBSHXRXQL7, PubMed 24926085

Vaksman O, Tropé C, Davidson B, Reich R (2014)
Exosome-derived miRNAs and ovarian carcinoma progression
35 (9), 2113-20
DOI 10.1093/carcin/bgu130, PubMed 24925027

Vilming Elgaaen B, Olstad OK, Haug KB, Brusletto B, Sandvik L, Staff AC, Gautvik KM, Davidson B (2014)
Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker
14, 80
DOI 10.1186/1471-2407-14-80, PubMed 24512620

Publications 2013

Azad N, Yu M, Davidson B, Choyke P, Chen CC, Wood BJ, Venkatesan A, Henning R, Calvo K, Minasian L, Edelman DC, Meltzer P, Steinberg SM, Annunziata CM, Kohn EC (2013)
Translational Predictive Biomarker Analysis of the Phase 1b Sorafenib and Bevacizumab Study Expansion Cohort
Mol. Cell. Proteomics, 12 (6), 1621-1631
DOI 10.1074/mcp.M112.026427

Ben-Hur V, Denichenko P, Siegfried Z, Maimon A, Krainer A, Davidson B, Karni R (2013)
S6K1 Alternative Splicing Modulates Its Oncogenic Activity and Regulates mTORC1
Cell Reports, 3 (1), 103-115
DOI 10.1016/j.celrep.2012.11.020

Davidson B (2013)
Hepatocyte nuclear factor-1β is not a specific marker of clear cell carcinoma in serous effusions
122 (2), 153-8
DOI 10.1002/cncy.21353, PubMed 24115587

Davidson B, Abeler VM, Førsund M, Holth A, Yang Y, Kobayashi Y, Chen L, Kristensen GB, Shih IeM, Wang TL (2013)
Gene expression signatures of primary and metastatic uterine leiomyosarcoma
45 (4), 691-700
DOI 10.1016/j.humpath.2013.11.003, PubMed 24485798

Davidson B, Smith Y, Nesland JM, Kærn J, Reich R, Tropè CG (2013)
Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion
44 (11), 2449-60
DOI 10.1016/j.humpath.2013.06.003, PubMed 24011953

Hoang LN, McConechy MK, Kobel M, Han GM, Rouzbahman M, Davidson B, Irving J, Ali RH, Leung S, McAlpine JN, Oliva E, Nucci MR, Soslow RA, Huntsman DG, Gilks CB, Lee CH (2013)
Histotype-Genotype Correlation in 36 High-grade Endometrial Carcinomas
Am. J. Surg. Pathol., 37 (9), 1421-1432

Micci F, Panagopoulos I, Haugom L, Dahlback HS, Pretorius ME, Davidson B, Abeler VM, Tropé CG, Danielsen HE, Heim S (2013)
Genomic aberration patterns and expression profiles of squamous cell carcinomas of the vulva
52 (6), 551-63
DOI 10.1002/gcc.22053, PubMed 23404381

Panagopoulos I, Thorsen J, Gorunova L, Haugom L, Bjerkehagen B, Davidson B, Heim S, Micci F (2013)
Fusion of the ZC3H7B and BCOR genes in endometrial stromal sarcomas carrying an X;22-translocation
52 (7), 610-8
DOI 10.1002/gcc.22057, PubMed 23580382

Panagopoulos I, Thorsen J, Gorunova L, Micci F, Haugom L, Davidson B, Heim S (2013)
RNA sequencing identifies fusion of the EWSR1 and YY1 genes in mesothelioma with t(14;22)(q32;q12)
52 (8), 733-40
DOI 10.1002/gcc.22068, PubMed 23630070

Sebban S, Golan-Gerstl R, Karni R, Vaksman O, Davidson B, Reich R (2013)
Alternatively spliced lysyl oxidase-like 4 isoforms have a pro-metastatic role in cancer
Clin. Exp. Metastasis, 30 (1), 103-117
DOI 10.1007/s10585-012-9514-0

Stavnes HT, Holth A, Don T, Kærn J, Vaksman O, Reich R, Trope' CG, Davidson B (2013)
HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival
129 (2), 358-63
DOI 10.1016/j.ygyno.2013.02.021, PubMed 23438671

Tan TZ, Miow QH, Huang RYJ, Wong MK, Ye JR, Lau JA, Wu MC, Hadi LHB, Soong R, Choolani M, Davidson B, Nesland JM, Wang LZ, Matsumura N, Mandai M, Konishi I, Goh BC, Chang JT, Thiery JP, Mori S (2013)
Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer
EMBO Mol. Med., 5 (7), 1051-1066
DOI 10.1002/emmm.201201823

Vaksman O, Davidson B, Trope C, Reich R (2013)
Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases
Hum. Pathol., 44 (12), 2677-2683
DOI 10.1016/j.humpath.2013.07.009

Vettukattil R, Hetland TE, Flørenes VA, Kærn J, Davidson B, Bathen TF (2013)
Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma
44 (9), 1859-66
DOI 10.1016/j.humpath.2013.02.009, PubMed 23656974

Publications 2012

Brenne K, Nymoen DA, Reich R, Davidson B (2012)
PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma
137 (2), 240-7
DOI 10.1309/AJCPGA95KVSAUDMF, PubMed 22261449

Brusegard K, Stavnes HT, Nymoen DA, Flatmark K, Trope CG, Davidson B (2012)
Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma
460 (2), 193-202
DOI 10.1007/s00428-011-1191-x, PubMed 22249560

Davidson B, Abeler VM, Hellesylt E, Holth A, Shih IeM, Skeie-Jensen T, Chen L, Yang Y, Wang TL (2012)
Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma
128 (2), 349-55
DOI 10.1016/j.ygyno.2012.11.021, PubMed 23178314

Davidson B, Dong HP, Berner A, Risberg B (2012)
The diagnostic and research applications of flow cytometry in cytopathology
40 (6), 525-35
DOI 10.1002/dc.22809, PubMed 22619127

Davidson B, Holth A, Nguyen MT, Tropé CG, Wu C (2012)
Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases
128 (2), 364-70
DOI 10.1016/j.ygyno.2012.10.015, PubMed 23099104

Davidson B, Tropé CG, Reich R (2012)
Epithelial-mesenchymal transition in ovarian carcinoma
2, 33
DOI 10.3389/fonc.2012.00033, PubMed 22655269

Elstrand MB, Sandstad B, Oksefjell H, Davidson B, Tropé CG (2012)
Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective
91 (3), 308-17
DOI 10.1111/j.1600-0412.2011.01316.x, PubMed 22050605

Gillet JP, Calcagno AM, Varma S, Davidson B, Elstrand MB, Ganapathi R, Kamat AA, Sood AK, Ambudkar SV, Seiden MV, Rueda BR, Gottesman MM (2012)
Multidrug Resistance-Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma
Clin. Cancer Res., 18 (11), 3197-3206
DOI 10.1158/1078-0432.CCR-12-0056

Hetland TE, Holth A, Kærn J, Flørenes VA, Tropé CG, Davidson B (2012)
HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases
460 (5), 505-13
DOI 10.1007/s00428-012-1228-9, PubMed 22476403

Hetland TE, Kærn J, Skrede M, Sandstad B, Tropé C, Davidson B, Flørenes VA (2012)
Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index
69 (5), 1307-14
DOI 10.1007/s00280-012-1835-9, PubMed 22302409

Hetland TE, Nymoen DA, Emilsen E, Kærn J, Tropé CG, Flørenes VA, Davidson B (2012)
MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival
126 (3), 460-5
DOI 10.1016/j.ygyno.2012.05.029, PubMed 22652154

Hetland TE, Nymoen DA, Holth A, Brusegard K, Flørenes VA, Kærn J, Tropé CG, Davidson B (2012)
Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance
44 (5), 777-85
DOI 10.1016/j.humpath.2012.08.002, PubMed 23114921

Hsu S, Kim M, Hernandez L, Grajales V, Noonan A, Anver M, Davidson B, Annunziata CM (2012)
IKK-epsilon Coordinates Invasion and Metastasis of Ovarian Cancer
Cancer Res., 72 (21), 5494-5504
DOI 10.1158/0008-5472.CAN-11-3993

Kim G, Davidson B, Henning R, Wang JB, Yu MS, Annunziata C, Hetland T, Kohn EC (2012)
Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome
Cancer, 118 (6), 1543-1553
DOI 10.1002/cncr.26449

Konstantinovsky S, Davidson B, Reich R (2012)
Ezrin and BCAR1/p130Cas mediate breast cancer growth as 3-D spheroids
Clin. Exp. Metastasis, 29 (6), 527-540
DOI 10.1007/s10585-012-9468-2

Panagopoulos I, Micci F, Thorsen J, Gorunova L, Eibak AM, Bjerkehagen B, Davidson B, Heim S (2012)
Novel fusion of MYST/Esa1-associated factor 6 and PHF1 in endometrial stromal sarcoma
7 (6), e39354
DOI 10.1371/journal.pone.0039354, PubMed 22761769

Pradhan M, Davidson B, Abeler VM, Danielsen HE, Tropé CG, Kristensen GB, Risberg BÅ (2012)
DNA ploidy may be a prognostic marker in stage I and II serous adenocarcinoma of the endometrium
461 (3), 291-8
DOI 10.1007/s00428-012-1275-2, PubMed 22824999

Stavnes HT, Nymoen DA, Langerød A, Holth A, Børresen Dale AL, Davidson B (2012)
AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma
462 (2), 163-73
DOI 10.1007/s00428-012-1347-3, PubMed 23242172

Tropé CG, Elstrand MB, Sandstad B, Davidson B, Oksefjell H (2012)
Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?
48 (14), 2146-54
DOI 10.1016/j.ejca.2012.01.031, PubMed 22382201

Tropé CG, Kaern J, Davidson B (2012)
Borderline ovarian tumours
26 (3), 325-36
DOI 10.1016/j.bpobgyn.2011.12.006, PubMed 22321906

Vaksman O, Hetland TE, Trope' CG, Reich R, Davidson B (2012)
Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma
Hum. Pathol., 43 (11), 2062-2069
DOI 10.1016/j.humpath.2012.02.016

Weiss I, Trope CG, Reich R, Davidson B (2012)
Hyaluronan Synthase and Hyaluronidase Expression in Serous Ovarian Carcinoma is Related to Anatomic Site and Chemotherapy Exposure
Int. J. Mol. Sci., 13 (10), 12925-12938
DOI 10.3390/ijms131012925

Publications 2011

Bock AJ, Dong HP, Tropé CG, Staff AC, Risberg B, Davidson B (2011)
Nucleoside transporters are widely expressed in ovarian carcinoma effusions
69 (2), 467-75
DOI 10.1007/s00280-011-1716-7, PubMed 21822668

Bock AJ, Nymoen DA, Brenne K, Kærn J, Davidson B (2011)
SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions
43 (5), 669-74
DOI 10.1016/j.humpath.2011.06.003, PubMed 21855113

Bock AJ, Tuft Stavnes H, Kærn J, Berner A, Staff AC, Davidson B (2011)
Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status
32 (3), 589-96
DOI 10.1007/s13277-011-0157-6, PubMed 21350924

Brenne K, Nymoen DA, Hetland TE, Trope' CG, Davidson B (2011)
Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival
43 (4), 496-505
DOI 10.1016/j.humpath.2011.05.023, PubMed 21855111

Davidson B, Holth A, Moripen L, Trope' CG, Shih IeM (2011)
Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome
42 (7), 991-7
DOI 10.1016/j.humpath.2010.10.013, PubMed 21315424

Davidson B, Stavnes HT, Holth A, Chen X, Yang Y, Shih IeM, Wang TL (2011)
Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions
15 (3), 535-44
DOI 10.1111/j.1582-4934.2010.01023.x, PubMed 20132413

Davidson B, Stavnes HT, Holth A, Chen X, Yang YQ, Shih IM, Wang TL (2011)
Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions
J. Cell. Mol. Med., 15 (3), 535-544
DOI 10.1111/j.1582-4934.2010.01019.x

Davidson B, Stavnes HT, Risberg B, Nesland JM, Wohlschlaeger J, Yang Y, Shih IeM, Wang TL (2011)
Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions
43 (5), 684-94
DOI 10.1016/j.humpath.2011.06.015, PubMed 21937081

Dong HP, Ree Rosnes AK, Bock AJ, Holth A, Flørenes VA, Trope' CG, Risberg B, Davidson B (2011)
Flow cytometric measurement of cellular FLICE-inhibitory protein (c-FLIP) in ovarian carcinoma effusions
22 (6), 373-82
DOI 10.1111/j.1365-2303.2011.00929.x, PubMed 22032542

Elstrand MB, Stavnes HT, Tropé CG, Davidson B (2011)
Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions
43 (4), 529-35
DOI 10.1016/j.humpath.2011.05.022, PubMed 21864883

Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, Patel C, Orina JN, Eliseeva TA, Singal V, Padmanabhan R, Davidson B, Ganapathi R, Sood AK, Rueda BR, Ambudkar SV, Gottesman MM (2011)
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance
Proc. Natl. Acad. Sci. U. S. A., 108 (46), 18708-18713
DOI 10.1073/pnas.1111840108

Gillett JP, Wang JB, Calcagno AM, Green LJ, Varma S, Elstrand MB, Trope CG, Ambudkar SV, Davidson B, Gottesman MM (2011)
Clinical Relevance of Multidrug Resistance Gene Expression in Ovarian Serous Carcinoma Effusions
Mol. Pharm., 8 (6), 2080-2088
DOI 10.1021/mp200240a

Hetland TE, Hellesylt E, Flørenes VA, Tropé C, Davidson B, Kærn J (2011)
Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance
42 (7), 1019-26
DOI 10.1016/j.humpath.2010.10.025, PubMed 21315408

Hoskins E, Rodriguez-Canales J, Hewitt SM, Elmasri W, Han J, Han S, Davidson B, Kohn EC (2011)
Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells
Gynecol. Oncol., 122 (3), 656-662
DOI 10.1016/j.ygyno.2011.04.052

Reich R, Hadar S, Davidson B (2011)
Expression and Clinical Role of Protein of Regenerating Liver (PRL) Phosphatases in Ovarian Carcinoma
Int. J. Mol. Sci., 12 (2), 1133-1145
DOI 10.3390/ijms12021133

Schmitt F, Cochand-Priollet B, Toetsch M, Davidson B, Bondi A, Vielh P (2011)
Immunocytochemistry in Europe: results of the European Federation of Cytology Societies (EFCS) inquiry
Cytopathology, 22 (4), 238-242
DOI 10.1111/j.1365-2303.2011.00885.x

Vaksman O, Stavnes HT, Kaern J, Trope CG, Davidson B, Reich R (2011)
miRNA profiling along tumour progression in ovarian carcinoma
J. Cell. Mol. Med., 15 (7), 1593-1602
DOI 10.1111/j.1582-4934.2010.01148.x

Yuan Y, Dong HP, Nymoen DA, Nesland JM, Wu C, Davidson B (2011)
PINCH-2 expression in cancers involving serosal effusions using quantitative PCR
22 (1), 22-9
DOI 10.1111/j.1365-2303.2010.00757.x, PubMed 20500520

Publications 2010

Annunziata CM, Stavnes HT, Kleinberg L, Berner A, Hernandez LF, Birrer MJ, Steinberg SM, Davidson B, Kohn EC (2010)
Nuclear Factor kappa B Transcription Factors Are Coexpressed and Convey a Poor Outcome in Ovarian Cancer
Cancer, 116 (13), 3276-3284
DOI 10.1002/cncr.25190

Bock AJ, Stavnes HT, Kempf T, Tropè CG, Berner A, Davidson B, Staff AC (2010)
Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions
20 (9), 1448-55
DOI 10.1111/IGC.0b013e3181f7d6be, PubMed 21336029

Bunkholt Elstrand M, Dong HP, Ødegaard E, Holth A, Elloul S, Reich R, Tropé CG, Davidson B (2010)
Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma
41 (6), 794-804
DOI 10.1016/j.humpath.2009.09.017, PubMed 20153512

Davidson B (2010)
The diagnostic and molecular characteristics of malignant mesothelioma and ovarian/peritoneal serous carcinoma
22 (1), 5-21
DOI 10.1111/j.1365-2303.2010.00829.x, PubMed 21114695

Davidson B, Reich R, Trope CG, Wang TL, Shih IeM (2010)
New determinates of disease progression and outcome in metastatic ovarian carcinoma
25 (12), 1591-609
DOI 10.14670/HH-25.1591, PubMed 20886439

Davidson B, Reich R, Trope CG, Wang TL, Shih IM (2010)
New determinates of disease progression and outcome in metastatic ovarian carcinoma
Histol. Histopath., 25 (12), 1591-1609

Davidson B, Stavnes HT, Førsund M, Berner A, Staff AC (2010)
CD105 (Endoglin) expression in breast carcinoma effusions is a marker of poor survival
19 (6), 493-8
DOI 10.1016/j.breast.2010.05.013, PubMed 21078485

Dong HP, Holth A, Ruud MG, Emilsen E, Risberg B, Davidson B (2010)
Measurement of apoptosis in cytological specimens by flow cytometry: comparison of Annexin V, caspase cleavage and dUTP incorporation assays
22 (6), 365-72
DOI 10.1111/j.1365-2303.2010.00811.x, PubMed 21054589

Elloul S, Vaksman O, Stavnes HT, Trope CG, Davidson B, Reich R (2010)
Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions
Clin. Exp. Metastasis, 27 (3), 161-172
DOI 10.1007/s10585-010-9315-2

Flatmark K, Davidson B, Kristian A, Stavnes HT, Førsund M, Reed W (2010)
Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models
41 (8), 1109-19
DOI 10.1016/j.humpath.2009.12.013, PubMed 20338618

Hernandez L, Hsu SC, Davidson B, Birrer MJ, Kohn EC, Annunziata CM (2010)
Activation of NF-KB Signaling by Inhibitor of NF-KB Kinase beta Increases Aggressiveness of Ovarian Cancer
Cancer Res., 70 (10), 4005-4014
DOI 10.1158/0008-5472.CAN-09-3912

Jinawath N, Vasoontara C, Jinawath A, Fang XP, Zhao KJ, Yap KL, Guo T, Lee CS, Wang WJ, Balgley BM, Davidson B, Wang TL, Shih IM (2010)
Oncoproteomic Analysis Reveals Co-Upregulation of RELA and STAT5 in Carboplatin Resistant Ovarian Carcinoma
PLoS One, 5 (6), e11198
DOI 10.1371/journal.pone.0011198

Konstantinovsky S, Smith Y, Zilber S, Stavnes HT, Becker AM, Nesland JM, Reich R, Davidson B (2010)
Breast Carcinoma Cells in Primary Tumors and Effusions Have Different Gene Array Profiles
J. Oncol., 2010, 969084
DOI 10.1155/2010/969084

Micci F, Haugom L, Ahlquist T, Andersen HK, Abeler VM, Davidson B, Trope CG, Lothe RA, Heim S (2010)
Genomic aberrations in borderline ovarian tumors
8, 21
DOI 10.1186/1479-5876-8-21, PubMed 20184781

Oy GF, Slipicevic A, Davidson B, Solberg Faye R, Maelandsmo GM, Flørenes VA (2010)
Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma
126 (2), 350-61
DOI 10.1002/ijc.24727, PubMed 19588500

Park JT, Chen X, Trope CG, Davidson B, Shih IM, Wang TL (2010)
Notch3 Overexpression Is Related to the Recurrence of Ovarian Cancer and Confers Resistance to Carboplatin
Am. J. Pathol., 177 (3), 1087-1094
DOI 10.2353/ajpath.2010.100316

Pradhan M, Abeler VM, Davidson B, Kildal W, Nybøen A, Tropé CG, Risberg B, Danielsen HE (2010)
DNA ploidy heterogeneity in endometrial carcinoma: comparison between curettage and hysterectomy specimens
29 (6), 572-8
DOI 10.1097/PGP.0b013e3181e2e8ee, PubMed 20881853

Shih IM, Chen L, Wang CC, Gu JH, Davidson B, Cope L, Kurman RJ, Xuan JH, Wang TL (2010)
Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis
Am. J. Obstet. Gynecol., 203 (6), 584.e1
DOI 10.1016/j.ajog.2010.08.003

Staff AC, Bock AJ, Becker C, Kempf T, Wollert KC, Davidson B (2010)
Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer
118 (3), 237-43
DOI 10.1016/j.ygyno.2010.05.032, PubMed 20576287

Ueda SM, Yap KL, Davidson B, Tian Y, Murthy V, Wang TL, Visvanathan K, Kuhajda FP, Bristow RE, Zhang H, Shih IM (2010)
Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas
J. Oncol., 2010, 285191
DOI 10.1155/2010/285191

Wang TL, Davidson B, Buckhaults PJ, Huang CS, Pohl G (2010)
Molecular Genetic Markers in Female Reproductive Cancers
J. Oncol., 2010, 307460
DOI 10.1155/2010/307460

Yu GQ, Feng YJ, Miller DJ, Xuan JH, Hoffman EP, Clarke R, Davidson B, Shih IM, Wang Y (2010)
Matched Gene Selection and Committee Classifier for Molecular Classification of Heterogeneous Diseases
J. Mach. Learn. Res., 11, 2141-2167

Yuan Y, Leszczynska M, Konstantinovsky S, Tropé CG, Reich R, Davidson B (2010)
Netrin-4 is upregulated in breast carcinoma effusions compared to corresponding solid tumors
39 (8), 562-6
DOI 10.1002/dc.21424, PubMed 20730893

Publications 2009

Davidson B, Hadar R, Stavnes HT, Trope' CG, Reich R (2009)
Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival
40 (5), 705-13
DOI 10.1016/j.humpath.2008.09.019, PubMed 19157507

Dong HP, Holth A, Kleinberg L, Ruud MG, Elstrand MB, Tropé CG, Davidson B, Risberg B (2009)
Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma effusions using the annexin-V/7-AAD assay: clinical relevance and comparison with other apoptosis parameters
132 (5), 756-62
DOI 10.1309/AJCPAVFA8J3KHPRS, PubMed 19846818

Elstrand MB, Kleinberg L, Kohn EC, Tropé CG, Davidson B (2009)
Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma
28 (3), 211-21
DOI 10.1097/PGP.0b013e31818b0f5e, PubMed 19620938

Kleinberg L, Davidson B (2009)
Cell survival and apoptosis-related molecules in cancer cells in effusions: a comprehensive review
37 (8), 613-24
DOI 10.1002/dc.21095, PubMed 19418469

Kleinberg L, Dong HP, Holth A, Risberg B, Trope' CG, Nesland JM, Flørenes VA, Davidson B (2009)
Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma
40 (6), 795-806
DOI 10.1016/j.humpath.2008.10.019, PubMed 19157506

Maelandsmo GM, Flørenes VA, Nguyen MT, Flatmark K, Davidson B (2009)
Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites
30 (1), 15-25
DOI 10.1159/000199447, PubMed 19194111

Pradhan M, Davidson B, Tropé CG, Danielsen HE, Abeler VM, Risberg B (2009)
Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas--an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications
454 (6), 677-83
DOI 10.1007/s00428-009-0778-y, PubMed 19421773

Pretorius ME, Waehre H, Abeler VM, Davidson B, Vlatkovic L, Lothe RA, Giercksky KE, Danielsen HE (2009)
Large scale genomic instability as an additive prognostic marker in early prostate cancer
31 (4), 251-9
DOI 10.3233/CLO-2009-0463, PubMed 19633362

Sebban S, Davidson B, Reich R (2009)
Lysyl oxidase-like 4 is alternatively spliced in an anatomic site-specific manner in tumors involving the serosal cavities
Virchows Arch., 454 (1), 71-79
DOI 10.1007/s00428-008-0694-6

Shih IM, Davidson B (2009)
Pathogenesis of ovarian cancer: clues from selected overexpressed genes
Future Oncol., 5 (10), 1641-1657
DOI 10.2217/FON.09.126

Slipicevic A, Øy GF, Askildt IC, Holth A, Hellesylt E, Flørenes VA, Davidson B (2009)
Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions
40 (4), 527-37
DOI 10.1016/j.humpath.2008.10.003, PubMed 19121847

Tropé C, Davidson B, Paulsen T, Abeler VM, Kaern J (2009)
Diagnosis and treatment of borderline ovarian neoplasms "the state of the art"
30 (5), 471-82
PubMed 19899396

Trope C, Davidson B, Paulsen T, Abeler VM, Kaern J (2009)
Diagnosis and treatment of borderline ovarian neoplasms "the state of the art"
Eur. J. Gynaecol. Oncol., 30 (5), 471-482

Yuan Y, Nymoen DA, Dong HP, Bjørang O, Shih IeM, Low PS, Trope' CG, Davidson B (2009)
Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions
40 (10), 1453-60
DOI 10.1016/j.humpath.2009.02.013, PubMed 19454358

Yuan Y, Nymoen DA, Stavnes HT, Rosnes AK, Bjorang O, Wu CY, Nesland JM, Davidson B (2009)
Tenascin-X is a Novel Diagnostic Marker of Malignant Mesothelioma
Am. J. Surg. Pathol., 33 (11), 1673-1682
DOI 10.1097/PAS.0b013e3181b6bde3

Publications 2008

Choi JH, Park JT, Davidson B, Morin PJ, Shih IM, Wang TL (2008)
Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion
Cancer Res., 68 (14), 5716-5723
DOI 10.1158/0008-5472.CAN-08-0001

Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih IM, Zhang YQ, Wood W, Becker KG, Morin PJ (2008)
MicroRNA Expression and Identification of Putative miRNA Targets in Ovarian Cancer
PLoS One, 3 (6), e2436
DOI 10.1371/journal.pone.0002436

Davidson B (2008)
New diagnostic and molecular characteristics of malignant mesothelioma
32 (6), 227-40
DOI 10.1080/01913120802454298, PubMed 19117264

Davidson B, Dong HP, Holth A, Berner A, Risberg B (2008)
The chemokine receptor CXCR4 is more frequently expressed in breast compared to other metastatic adenocarcinomas in effusions
14 (5), 476-82
DOI 10.1111/j.1524-4741.2008.00625.x, PubMed 18657145

Davidson B, Shih IeM, Wang TL (2008)
Different clinical roles for p21-activated kinase-1 in primary and recurrent ovarian carcinoma
39 (11), 1630-6
DOI 10.1016/j.humpath.2008.03.009, PubMed 18656238

Davidson B, Wang TL, Shih IeM, Berner A (2008)
Expression of the chromatin remodeling factor Rsf-1 is down-regulated in breast carcinoma effusions
39 (4), 616-22
DOI 10.1016/j.humpath.2007.09.008, PubMed 18289639

Dong HP, Kleinberg L, Davidson B, Risberg B (2008)
Methods for simultaneous measurement of apoptosis and cell surface phenotype of epithelial cells in effusions by flow cytometry
3 (6), 955-64
DOI 10.1038/nprot.2008.77, PubMed 18546596

Dong HP, Kleinberg L, Silins I, Flørenes VA, Tropé CG, Risberg B, Nesland JM, Davidson B (2008)
Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma
112 (1), 84-93
DOI 10.1002/cncr.23140, PubMed 17985388

Kleinberg L, Holth A, Trope CG, Reich R, Davidson B (2008)
Claudin upregulation in ovarian carcinoma effusions is associated with poor survival
39 (5), 747-57
DOI 10.1016/j.humpath.2007.10.002, PubMed 18439941

Kleinberg L, Pradhan M, Tropé CG, Nesland JM, Davidson B, Risberg B (2008)
Ovarian carcinoma cells in effusions show increased S-phase fraction compared to corresponding primary tumors
36 (9), 637-44
DOI 10.1002/dc.20879, PubMed 18677760

Rayhman O, Klipper E, Muller L, Davidson B, Reich R, Meidan R (2008)
Small Interfering RNA Molecules Targeting Endothelin-Converting Enzyme-1 Inhibit Endothelin-1 Synthesis and the Invasive Phenotype of Ovarian Carcinoma Cells
Cancer Res., 68 (22), 9265-9273
DOI 10.1158/0008-5472.CAN-08-2093

Slipicevic A, Jørgensen K, Skrede M, Rosnes AK, Trøen G, Davidson B, Flørenes VA (2008)
The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells
8, 276
DOI 10.1186/1471-2407-8-276, PubMed 18826602

Ødegaard E, Davidson B, Elgaaen BV, Fagerhol MK, Engh V, Onsrud M, Staff AC (2008)
Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary
198 (4), 418.e1-7
DOI 10.1016/j.ajog.2007.10.792, PubMed 18241816

Ødegaard E, Davidson B, Engh V, Onsrud M, Staff AC (2008)
Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary
199 (5), 533.e1-8
DOI 10.1016/j.ajog.2008.04.004, PubMed 18533117

Publications 2007

Annunziata CM, Kleinberg L, Davidson B, Berner A, Gius D, Tchabo N, Steinberg SM, Kohn EC (2007)
BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancer
13 (22 Pt 1), 6585-92
DOI 10.1158/1078-0432.CCR-07-0327, PubMed 18006758

Davidson B (2007)
Anatomic site-related expression of cancer-associated molecules in ovarian carcinoma
7 (1), 109-20
DOI 10.2174/156800907780006904, PubMed 17305482

Davidson B (2007)
Biological characteristics of cancers involving the serosal cavities
13 (3), 189-227
DOI 10.1615/critrevoncog.v13.i3.10, PubMed 18298385

Davidson B (2007)
Expression of cancer-associated molecules in malignant mesothelioma
2, 173-84
PubMed 19662202

Davidson B (2007)
Expression of Cancer-Associated Molecules in Malignant Mesothelioma
Biomark. Insights, 2, 173-184

Davidson B, Baekelandt M, Shih IeM (2007)
MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells
35 (12), 756-60
DOI 10.1002/dc.20771, PubMed 18008338

Davidson B, Berner A, Trope' CG, Wang TL, Shih IM (2007)
Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions
38 (7), 1030-1036
DOI 10.1016/j.humpath.2006.12.009, PubMed 17391728

Davidson B, Dong HP, Holth A, Berner A, Risberg B (2007)
Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells
127 (5), 752-9
DOI 10.1309/LN2075V7C8K31CH8, PubMed 17439834

Davidson B, Dong HP, Holth A, Berner A, Risberg B (2007)
Flow cytometric immunophenotyping of cancer cells in effusion specimens: diagnostic and research applications
35 (9), 568-78
DOI 10.1002/dc.20707, PubMed 17703449

Davidson B, Hadar R, Schlossberg A, Sternlicht T, Slipicevic A, Skrede M, Risberg B, Flørenes VA, Kopolovic J, Reich R (2007)
Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma
39 (1), 87-95
DOI 10.1016/j.humpath.2007.05.014, PubMed 17949781

Davidson B, Skrede M, Silins I, Shih IeM, Trope CG, Flørenes VA (2007)
Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma
110 (6), 1264-71
DOI 10.1002/cncr.22918, PubMed 17647260

Davidson B, Xi Z, Saatcioglu F (2007)
Kallikrein 4 is expressed in malignant mesothelioma--further evidence for the histogenetic link between mesothelial and epithelial cells
35 (2), 80-4
DOI 10.1002/dc.20588, PubMed 17230566

Dong HP, Holth A, Berner A, Davidson B, Risberg B (2007)
Flow cytometric immunphenotyping of epithelial cancer cells in effusions--technical considerations and pitfalls
72 (5), 332-43
DOI 10.1002/cyto.b.20172, PubMed 17226863

Kleinberg L, Flørenes VA, Nesland JM, Davidson B (2007)
Survivin, a member of the inhibitors of apoptosis family, is down-regulated in breast carcinoma effusions
128 (3), 389-97
DOI 10.1309/E899BG1282M5D505, PubMed 17709312

Kleinberg L, Flørenes VA, Silins I, Haug K, Trope CG, Nesland JM, Davidson B (2007)
Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma
109 (2), 228-38
DOI 10.1002/cncr.22426, PubMed 17167759

Kleinberg L, Holth A, Fridman E, Schwartz I, Shih IeM, Davidson B (2007)
The diagnostic role of claudins in serous effusions
127 (6), 928-37
DOI 10.1309/V025QRN3R9CJGNPX, PubMed 17509990

Kleinberg L, Lie AK, Flørenes VA, Nesland JM, Davidson B (2007)
Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma
38 (7), 986-994
DOI 10.1016/j.humpath.2006.12.013, PubMed 17350081

Salani R, Davidson B, Fiegl M, Marth C, Müller-Holzner E, Gastl G, Huang HY, Hsiao JC, Lin HS, Wang TL, Lin BL, Shih IeM (2007)
Measurement of cyclin E genomic copy number and strand length in cell-free DNA distinguish malignant versus benign effusions
13 (19), 5805-9
DOI 10.1158/1078-0432.CCR-07-0853, PubMed 17908972

Sudbo J, Bryne M, Mao L, Lotan R, Reith A, Kildal W, Davidson B, Soland TM, Lippman SM (2007)
Molecular based treatment of oral cancer (Retraction of vol 39, pg 749, 2003)
Oral Oncol., 43 (4), 421
DOI 10.1016/j.oraloncology.2007.01.004

Publications 2006

Bassarova AV, Nesland JM, Davidson B (2006)
D2-40 is not a specific marker for cells of mesothelial origin in serous effusions
30 (7), 878-82
DOI 10.1097/01.pas.0000208280.29291.34, PubMed 16819331

Berner A, Sigstad E, Pradhan M, Grøholt KK, Davidson B (2006)
Fine-needle aspiration cytology of the thyroid gland: comparative analysis of experience at three hospitals
34 (2), 97-100
DOI 10.1002/dc.20384, PubMed 16514672

Davidson B, Espina V, Steinberg SM, Flørenes VA, Liotta LA, Kristensen GB, Tropé CG, Berner A, Kohn EC (2006)
Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling
12 (3 Pt 1), 791-9
DOI 10.1158/1078-0432.CCR-05-2516, PubMed 16467090

Davidson B, Konstantinovsky S, Kleinberg L, Nguyen MT, Bassarova A, Kvalheim G, Nesland JM, Reich R (2006)
The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma
102 (3), 453-61
DOI 10.1016/j.ygyno.2006.01.034, PubMed 16494928

Davidson B, Risberg B, Berner A, Bedrossian CW, Reich R (2006)
The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma
23 (1), 35-43
DOI 10.1053/j.semdp.2006.06.003, PubMed 17044194

Davidson B, Shafat I, Risberg B, Ilan N, Trope' CG, Vlodavsky I, Reich R (2006)
Heparanase expression correlates with poor survival in metastatic ovarian carcinoma
104 (2), 311-9
DOI 10.1016/j.ygyno.2006.08.045, PubMed 17030350

Davidson B, Trope' CG, Wang TL, Shih IeM (2006)
Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival
103 (3), 814-9
DOI 10.1016/j.ygyno.2006.05.042, PubMed 16844205

Davidson B, Zhang Z, Kleinberg L, Li M, Flørenes VA, Wang TL, Shih IeM (2006)
Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma
12 (20 Pt 1), 5944-50
DOI 10.1158/1078-0432.CCR-06-1059, PubMed 17062665

Dong HP, Elstrand MB, Holth A, Silins I, Berner A, Trope CG, Davidson B, Risberg B (2006)
NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma
125 (3), 451-8
PubMed 16613351

Dong HP, Elstrand MB, Holth A, Silins I, Berner A, Trope CG, Davidson B, Risberg B (2006)
NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma
Am. J. Clin. Pathol., 125 (3), 451-458
DOI 10.1309/15B66DQMFYYM78CJ

Elloul S, Silins I, Tropé CG, Benshushan A, Davidson B, Reich R (2006)
Expression of E-cadherin transcriptional regulators in ovarian carcinoma
449 (5), 520-8
DOI 10.1007/s00428-006-0274-6, PubMed 17024425

Gorovetz M, Baekelandt M, Berner A, Trope' CG, Davidson B, Reich R (2006)
The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma
103 (3), 831-40
DOI 10.1016/j.ygyno.2006.06.042, PubMed 16919315

Gotlieb WH, Bruchim I, Ben-Baruch G, Davidson B, Zeltser A, Andersen A, Olsen H (2006)
Doxorubicin levels in the serum and ascites of patients with ovarian cancer
33 (2), 213-5
DOI 10.1016/j.ejso.2006.11.006, PubMed 17174514

Jørgensen K, Davidson B, Flørenes VA (2006)
Activation of c-jun N-terminal kinase is associated with cell proliferation and shorter relapse-free period in superficial spreading malignant melanoma
19 (11), 1446-55
DOI 10.1038/modpathol.3800662, PubMed 16951673

Kleinberg L, Flørenes VA, Skrede M, Dong HP, Nielsen S, McMaster MT, Nesland JM, Shih IeM, Davidson B (2006)
Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma
449 (1), 31-9
DOI 10.1007/s00428-005-0144-7, PubMed 16541284

Nakayama K, Nakayama N, Davidson B, Katabuchi H, Kurman RJ, Velculescu VE, Shih IeM, Wang TL (2006)
Homozygous deletion of MKK4 in ovarian serous carcinoma
5 (6), 630-4
DOI 10.4161/cbt.5.6.2675, PubMed 16627982

Nakayama K, Nakayama N, Davidson B, Sheu JJ, Jinawath N, Santillan A, Salani R, Bristow RE, Morin PJ, Kurman RJ, Wang TL, Shih IeM (2006)
A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival
103 (49), 18739-44
DOI 10.1073/pnas.0604083103, PubMed 17130457

Park JT, Li M, Nakayama K, Mao TL, Davidson B, Zhang Z, Kurman RJ, Eberhart CG, Shih IeM, Wang TL (2006)
Notch3 gene amplification in ovarian cancer
66 (12), 6312-8
DOI 10.1158/0008-5472.CAN-05-3610, PubMed 16778208

Rocha AS, Risberg B, Magalhães J, Trovisco V, de Castro IV, Lazarovici P, Soares P, Davidson B, Sobrinho-Simões M (2006)
The p75 neurotrophin receptor is widely expressed in conventional papillary thyroid carcinoma
37 (5), 562-8
DOI 10.1016/j.humpath.2005.12.016, PubMed 16647954

Sivertsen S, Berner A, Michael CW, Bedrossian C, Davidson B (2006)
Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions
50 (6), 603-7
DOI 10.1159/000326027, PubMed 17152269

Sivertsen S, Hadar R, Elloul S, Vintman L, Bedrossian C, Reich R, Davidson B (2006)
Expression of Snail, Slug and Sip1 in malignant mesothelioma effusions is associated with matrix metalloproteinase, but not with cadherin expression
54 (3), 309-17
DOI 10.1016/j.lungcan.2006.08.010, PubMed 16996643

Ødegaard E, Staff AC, Abeler VM, Kopolovic J, Onsrud M, Lazarovici P, Davidson B (2006)
The activated nerve growth factor receptor p-TrkA is selectively expressed in advanced-stage ovarian carcinoma
38 (1), 140-6
DOI 10.1016/j.humpath.2006.06.027, PubMed 16996570

Publications 2005

Chen YC, Davidson B, Cheng CC, Maitra A, Giuntoli RL, Hruban RH, Wang TL, Shih IeM (2005)
Identification and characterization of membralin, a novel tumor-associated gene, in ovarian carcinoma
1730 (2), 96-102
DOI 10.1016/j.bbaexp.2005.06.008, PubMed 16084606

Chen YC, Pohl G, Wang TL, Morin PJ, Risberg B, Kristensen GB, Yu A, Davidson B, Shih IeM (2005)
Apolipoprotein E is required for cell proliferation and survival in ovarian cancer
65 (1), 331-7
PubMed 15665311

Chen YC, Pohl G, Wang TL, Morin PJ, Risberg B, Kristensen GB, Yu A, Davidson B, Shih IM (2005)
Apolipoprotein E is required for cell proliferation and survival in ovarian cancer
Cancer Res., 65 (1), 331-337

Davidson B, Abeler VM (2005)
Primary ovarian angiosarcoma presenting as malignant cells in ascites: case report and review of the literature
32 (5), 307-9
DOI 10.1002/dc.20245, PubMed 15830366

Davidson B, Elstrand MB, McMaster MT, Berner A, Kurman RJ, Risberg B, Trope CG, Shih IeM (2005)
HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma
96 (1), 42-7
DOI 10.1016/j.ygyno.2004.09.049, PubMed 15589578

Davidson B, Vintman L, Nielsen S, Reich R, Berner A (2005)
Site-related expression of metastasis-associated and signaling molecules in malignant mesothelioma--a new model for the study of tumor biology and disease progression
49 Suppl 1, S89-93
DOI 10.1016/j.lungcan.2005.03.026, PubMed 15950809

Davidson B, Xi Z, Klokk TI, Tropé CG, Dørum A, Scheistrøen M, Saatcioglu F (2005)
Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions
123 (3), 360-8
DOI 10.1309/PTBB-5BPC-KX8K-9V69, PubMed 15716231

Davidson B, Xi ZJ, Klokk TI, Trope CG, Dorum A, Scheistroen M, Saatcioglu F (2005)
Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions
Am. J. Clin. Pathol., 123 (3), 360-368
DOI 10.1309/PTBB5BPCKX8K9V69

Elloul S, Elstrand MB, Nesland JM, Tropé CG, Kvalheim G, Goldberg I, Reich R, Davidson B (2005)
Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma
103 (8), 1631-43
DOI 10.1002/cncr.20946, PubMed 15742334

Givant-Horwitz V, Davidson B, Reich R (2005)
Laminin-induced signaling in tumor cells
223 (1), 1-10
DOI 10.1016/j.canlet.2004.08.030, PubMed 15890231

Konstantinovsky S, Nielsen S, Vyberg M, Kvalheim G, Nesland JM, Reich R, Davidson B (2005)
Angiogenic molecule expression is downregulated in effusions from breast cancer patients
94 (1), 71-80
DOI 10.1007/s10549-005-7328-3, PubMed 16142438

Reich R, Vintman L, Nielsen S, Kaern J, Bedrossian C, Berner A, Davidson B (2005)
Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities
33 (5), 332-7
DOI 10.1002/dc.20296, PubMed 16240397

Schaner ME, Davidson B, Skrede M, Reich R, Flørenes VA, Risberg B, Berner A, Goldberg I, Givant-Horwitz V, Tropè CG, Kristensen GB, Nesland JM, Børresen-Dale AL (2005)
Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients
4, 26
DOI 10.1186/1476-4598-4-26, PubMed 16042759

Shih IeM, Sheu JJ, Santillan A, Nakayama K, Yen MJ, Bristow RE, Vang R, Parmigiani G, Kurman RJ, Trope CG, Davidson B, Wang TL (2005)
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma
102 (39), 14004-9
DOI 10.1073/pnas.0504195102, PubMed 16172393

Sigstad E, Dong HP, Nielsen S, Berner A, Davidson B, Risberg B (2005)
Quantitative analysis of integrin expression in effusions using flow cytometric immunophenotyping
33 (5), 325-31
DOI 10.1002/dc.20282, PubMed 16240402

Slipicevic A, Holm R, Nguyen MT, Bøhler PJ, Davidson B, Flørenes VA (2005)
Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome
124 (4), 528-36
DOI 10.1309/YT58WWMTA6YR1PRV, PubMed 16146807

Stevens EV, Raffeld M, Espina V, Kristensen GB, Trope' CG, Kohn EC, Davidson B (2005)
Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma
103 (11), 2313-9
DOI 10.1002/cncr.21031, PubMed 15844177

Sudbo J, Samuelsson R, Risberg B, Heistein S, Nyhus C, Samuelsson M, Puntervold R, Sigstad E, Davidson B, Reith A, Berner A (2005)
RETRACTED: Risk markers of oral cancer in clinically normal mucosa as an aid in smoking cessation counseling (Retracted Article. See vol 24, pg 5621, 2006)
J. Clin. Oncol., 23 (9), 1927-1933
DOI 10.1200/JCO.2005.03.172

Vintman L, Nielsen S, Berner A, Reich R, Davidson B (2005)
Mitogen-activated protein kinase expression and activation does not differentiate benign from malignant mesothelial cells
103 (11), 2427-33
DOI 10.1002/cncr.21014, PubMed 15830375

Ødegaard E, Staff AC, Kaern J, Flørenes VA, Kopolovic J, Tropé CG, Abeler VM, Reich R, Davidson B (2005)
The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma
100 (3), 462-8
DOI 10.1016/j.ygyno.2005.09.022, PubMed 16216317

Publications 2004

Davidson B (2004)
Malignant effusions: from diagnosis to biology
31 (4), 246-54
DOI 10.1002/dc.20133, PubMed 15452897

Davidson B, Alejandro E, Flørenes VA, Goderstad JM, Risberg B, Kristensen GB, Trope CG, Kohn EC (2004)
Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma
100 (10), 2139-47
DOI 10.1002/cncr.20219, PubMed 15139056

Davidson B, Goldberg I, Tell L, Vigdorchik S, Baekelandt M, Berner A, Kristensen GB, Reich R, Kopolovic J (2004)
The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions
21 (3), 191-9
DOI 10.1023/b:clin.0000037703.37275.35, PubMed 15387369

Davidson B, Konstantinovsky S, Nielsen S, Dong HP, Berner A, Vyberg M, Reich R (2004)
Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression
10 (21), 7335-46
DOI 10.1158/1078-0432.CCR-04-0183, PubMed 15534110

Davidson B, Reich R, Lazarovici P, Ann Flørenes V, Nielsen S, Nesland JM (2004)
Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma
83 (2), 119-28
DOI 10.1023/B:BREA.0000010704.17479.8a, PubMed 14997042

Davidson B, Reich R, Lazarovici P, Flørenes VA, Risberg B, Nielsen S, Sert B, Bedrossian C (2004)
Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma
44 (2), 159-65
DOI 10.1016/j.lungcan.2003.11.014, PubMed 15084380

Davidson B, Suo Z, Nesland JM (2004)
Malignant mesothelioma
28 (4), 179-80
DOI 10.1080/01913120490518051, PubMed 15693629

Davidson B, Vintman L, Zcharia E, Bedrossian C, Berner A, Nielsen S, Ilan N, Vlodavsky I, Reich R (2004)
Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma
21 (5), 469-76
DOI 10.1007/s10585-004-3150-2, PubMed 15672872

Florenes VA, Maelandsmo GM, Holm R, Reich R, Lazarovici P, Davidson B (2004)
Expression of activated TrkA protein in melanocytic tumors - Relationship to cell proliferation and clinical outcome
Am. J. Clin. Pathol., 122 (3), 412-420
DOI 10.1309/CHFHEYAT44WWP7J3

Flørenes VA, Maelandsmo GM, Holm R, Reich R, Lazarovici P, Davidson B (2004)
Expression of activated TrkA protein in melanocytic tumors: relationship to cell proliferation and clinical outcome
122 (3), 412-20
DOI 10.1309/CHFH-EYAT-44WW-P7J3, PubMed 15362372

Givant-Horwitz V, Davidson B, Goderstad JM, Nesland JM, Tropé CG, Reich R (2004)
The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma
93 (2), 517-23
DOI 10.1016/j.ygyno.2004.03.009, PubMed 15099972

Givant-Horwitz V, Davidson B, Reich R (2004)
Laminin-induced signaling in tumor cells: the role of the M(r) 67,000 laminin receptor
64 (10), 3572-9
DOI 10.1158/0008-5472.CAN-03-3424, PubMed 15150114

Sigstad E, Dong HP, Davidson B, Berner A, Tierens A, Risberg B (2004)
The role of flow cytometric immunophenotyping in improving the diagnostic accuracy in referred fine-needle aspiration specimens
31 (3), 159-63
DOI 10.1002/dc.20108, PubMed 15349984

Xi Z, Kaern J, Davidson B, Klokk TI, Risberg B, Tropé C, Saatcioglu F (2004)
Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer
94 (1), 80-5
DOI 10.1016/j.ygyno.2004.03.044, PubMed 15262123

Publications 2003

Berner A, Davidson B, Sigstad E, Risberg B (2003)
Fine-needle aspiration cytology vs. core biopsy in the diagnosis of breast lesions
29 (6), 344-8
DOI 10.1002/dc.10372, PubMed 14648793

Davidson B, Givant-Horwitz V, Lazarovici P, Risberg B, Nesland JM, Trope CG, Schaefer E, Reich R (2003)
Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma
20 (7), 621-31
DOI 10.1023/a:1027347932543, PubMed 14669793

Davidson B, Goldberg I, Berner A, Kristensen GB, Reich R (2003)
EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma
20 (2), 161-9
DOI 10.1023/a:1022696012668, PubMed 12705637

Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Reich R (2003)
PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma
9 (4), 1412-9
PubMed 12684413

Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Reich R (2003)
PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma
Clin. Cancer Res., 9 (4), 1412-1419

Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Risberg B, Ben-Baruch G, Reich R (2003)
Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma: a possible activation pathway?
22 (1), 103-15
DOI 10.1023/a:1022272204045, PubMed 12716042

Davidson B, Goldberg I, Reich R, Tell L, Dong HP, Trope' CG, Risberg B, Kopolovic J (2003)
AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients
90 (2), 248-57
DOI 10.1016/s0090-8258(03)00321-4, PubMed 12893184

Davidson B, Reich R, Lazarovici P, Nesland JM, Skrede M, Risberg B, Trope CG, Florenes VA (2003)
Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma
Clin. Cancer Res., 9 (6), 2248-2259

Davidson B, Reich R, Lazarovici P, Nesland JM, Skrede M, Risberg B, Tropé CG, Flørenes VA (2003)
Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma
9 (6), 2248-59
PubMed 12796393

Davidson B, Risberg B, Reich R, Berner A (2003)
Effusion cytology in ovarian cancer: new molecular methods as aids to diagnosis and prognosis
23 (3), 729-54, viii
DOI 10.1016/s0272-2712(03)00058-1, PubMed 14560537

Givant-Horwitz V, Davidson B, Lazarovici P, Schaefer E, Nesland JM, Tropé CG, Reich R (2003)
Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions
91 (1), 160-72
DOI 10.1016/s0090-8258(03)00434-7, PubMed 14529677

Givant-Horwitz V, Davidson B, van de Putte G, Dong HP, Goldberg I, Amir S, Kristensen GB, Reich R (2003)
Expression of the 67 kDa laminin receptor and the alpha6 integrin subunit in serous ovarian carcinoma
20 (7), 599-609
DOI 10.1023/a:1027340208536, PubMed 14669791

Sudbo J, Bryne IM, Mao L, Lotan R, Reith A, Kildal W, Davidson B, Soland TM, Lippman SM (2003)
RETRACTED: Molecular based treatment of oral cancer (Retracted article. See vol 43, pg 421, 2007)
Oral Oncol., 39 (8), 749-758
DOI 10.1016/S1368-8375(03)00098-8

Publications 2002

Davidson B, Dong HP, Berner A, Christensen J, Nielsen S, Johansen P, Bryne M, Asschenfeldt P, Risberg B (2002)
Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping: an analysis of 92 cases
118 (1), 85-92
DOI 10.1309/M877-QABM-D9GB-FJAX, PubMed 12109861

Davidson B, Dong HP, Berner A, Christensen J, Nielsen S, Johansen P, Bryne M, Asschenfeldt P, Risberg B (2002)
Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping - An analysis of 92 cases
Am. J. Clin. Pathol., 118 (1), 85-92

Davidson B, Goldberg I, Givant-Horwitz V, Nesland JM, Berner A, Bryne M, Risberg B, Kopolovic J, Kristensen GB, Tropé CG, van de Putte G, Reich R (2002)
Caveolin-1 expression in ovarian carcinoma is MDR1 independent
117 (2), 225-34
DOI 10.1309/u40r-1bn4-6kj3-bdg3, PubMed 11863219

Davidson B, Goldberg I, Givant-Horwitz V, Nesland JM, Berner A, Bryne M, Risberg B, Kopolovic J, Kristensen GB, Trope CG, van de Putte G, Reich R (2002)
Caveolin-1 expression in ovarian carcinoma is MDR1 independent
Am. J. Clin. Pathol., 117 (2), 225-234

Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM, Reich R (2002)
The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma
187 (1-2), 39-45
DOI 10.1016/s0303-7207(01)00709-2, PubMed 11988310

Davidson B, Reich R, Kopolovic J, Berner A, Nesland JM, Kristensen GB, Tropé CG, Bryne M, Risberg B, van de Putte G, Goldberg I (2002)
Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions
19 (2), 135-44
DOI 10.1023/a:1014582911680, PubMed 11964077

Davidson B, Reich R, Risberg B, Nesland JM (2002)
The biological role and regulation of matrix metalloproteinases (MMP) in cancer
64 (3), 47-53
PubMed 15338725

Karbova E, Davidson B, Metodiev K, Tropé CG, Nesland JM (2002)
Adenomatous polyposis coli (APC) protein expression in primary and metastatic serous ovarian carcinoma
10 (3), 175-80
DOI 10.1177/106689690201000302, PubMed 12232570

Risberg B, Karlsson K, Abeler V, Lagrelius A, Davidson B, Karlsson MG (2002)
Dissociated expression of Bcl-2 and Ki-67 in endometrial lesions: diagnostic and histogenetic implications
21 (2), 155-60
DOI 10.1097/00004347-200204000-00008, PubMed 11917225

Ustün M, Berner A, Davidson B, Risberg B (2002)
Fine-needle aspiration cytology of lobular carcinoma in situ
27 (1), 22-6
DOI 10.1002/dc.10128, PubMed 12112810

Ustün M, Risberg B, Davidson B, Berner A (2002)
Cystic change in metastatic lymph nodes: a common diagnostic pitfall in fine-needle aspiration cytology
27 (6), 387-92
DOI 10.1002/dc.10201, PubMed 12451573

Publications 2001

Amitay R, Nass D, Meitar D, Goldberg I, Davidson B, Trakhtenbrot L, Brok-Simoni F, Ben-Ze'ev A, Rechavi G, Kaufmann Y (2001)
Reduced expression of plakoglobin correlates with adverse outcome in patients with neuroblastoma
159 (1), 43-9
DOI 10.1016/S0002-9440(10)61671-9, PubMed 11438452

Beiner ME, Gotlieb WH, Davidson B, Kopolovic J, Ben-Baruch G (2001)
Infertility treatment after conservative management of borderline ovarian tumors
92 (2), 320-5
DOI 10.1002/1097-0142(20010715)92:2<320::aid-cncr1325>3.0.co;2-g, PubMed 11466685

Davidson B (2001)
Ovarian carcinoma and serous effusions. Changing views regarding tumor progression and review of current literature
23 (3-4), 107-28
DOI 10.1155/2001/418547, PubMed 12082292

Davidson B (2001)
Ovarian carcinoma and serous effusions: a patho-biological study
Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Oslo, 1 b. (flere pag.)
BIBSYS 011165863, ISBN 82-7633-155-6

Davidson B, Goldberg I, Berner A, Nesland JM, Givant-Horwitz V, Bryne M, Risberg B, Kristensen GB, Tropé CG, Kopolovic J, Reich R (2001)
Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions
115 (4), 517-24
DOI 10.1309/B1YX-L8DB-TGY1-7905, PubMed 11293899

Davidson B, Goldberg I, Berner A, Nesland JM, Givant-Horwitz V, Byrne M, Risberg B, Kristensen GB, Trope CG, Kopolovic J, Reich R (2001)
Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions
Am. J. Clin. Pathol., 115 (4), 517-524

Davidson B, Goldberg I, Kopolovic J, Gotlieb WH, Givant-Horwitz V, Nesland JM, Berner A, Ben-Baruch G, Bryne M, Reich R (2001)
Expression of angiogenesis-related genes in ovarian carcinoma - A clinicopathologic study
Clin. Exp. Metastasis, 18 (6), 501-507

Davidson B, Lazarovici P, Ezersky A, Nesland JM, Berner A, Risberg B, Tropé CG, Kristensen GB, Goscinski M, van de Putte G, Reich R (2001)
Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients
7 (11), 3457-64
PubMed 11705863

Davidson B, Lazarovici P, Ezersky A, Nesland JM, Berner A, Risberg B, Trope CG, Kristensen GB, Goscinski M, van de Putte G, Reich R (2001)
Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients
Clin. Cancer Res., 7 (11), 3457-3464

Davidson B, Nesland JM, Goldberg I, Kopolovic J, Gotlieb WH, Bryne M, Ben-Baruch G, Berner A, Reich R (2001)
Caveolin-1 expression in advanced-stage ovarian carcinoma--a clinicopathologic study
81 (2), 166-71
DOI 10.1006/gyno.2001.6156, PubMed 11330944

Davidson B, Nielsen S, Christensen J, Asschenfeldt P, Berner A, Risberg B, Johansen P (2001)
The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells
25 (11), 1405-12
DOI 10.1097/00000478-200111000-00008, PubMed 11684957

Davidson B, Reich R, Berner A, Givant-Horwitz V, Goldberg I, Risberg B, Kristensen GB, Trope CG, Bryne M, Kopolovic J, Nesland JM (2001)
Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels
37 (16), 2040-9
DOI 10.1016/s0959-8049(01)00235-0, PubMed 11597382

Davidson B, Reich R, Goldberg I, Gotlieb WH, Kopolovic J, Berner A, Ben-Baruch G, Bryne M, Nesland JM (2001)
Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma
7 (3), 551-7
PubMed 11297247

Davidson B, Reich R, Goldberg I, Gotlieb WH, Kopolovic J, Berner A, Ben-Baruch G, Bryne M, Nesland JM (2001)
Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma
Clin. Cancer Res., 7 (3), 551-557

Davidson B, Risberg B, Berner A, Nesland JM, Tropé CG, Kristensen GB, Bryne M, Goscinski M, van de Putte G, Flørenes VA (2001)
Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications
83 (2), 249-56
DOI 10.1006/gyno.2001.6388, PubMed 11606079

Davidson B, Risberg B, Goldberg I, Nesland JM, Berner A, Tropé CG, Kristensen GB, Bryne M, Reich R (2001)
Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome
25 (12), 1493-500
DOI 10.1097/00000478-200112000-00004, PubMed 11717538

Goldberg I, Davidson B, Reich R, Gotlieb WH, Ben-Baruch G, Bryne M, Berner A, Nesland JM, Kopolovic J (2001)
Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma
7 (12), 4073-9
PubMed 11751504

Goldberg I, Davidson B, Reich R, Gotlieb WH, Ben-Baruch G, Bryne M, Berner A, Nesland JM, Kopolovic J (2001)
alpha v integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma
Clin. Cancer Res., 7 (12), 4073-4079

Gotlieb WH, Goldberg I, Weisz B, Davidson B, Novikov I, Kopolovic J, Ben-Baruch G (2001)
Topoisomerase II immunostaining as a prognostic marker for survival in ovarian cancer
82 (1), 99-104
DOI 10.1006/gyno.2001.6208, PubMed 11426969

Risberg B, Davidson B, Nielsen S, Dong HP, Christensen J, Johansen P, Asschenfeldt P, Berner A (2001)
Detection of monocyte/macrophage cell populations in effusions: a comparative study using flow cytometric immunophenotyping and immunocytochemistry
25 (4), 214-9
DOI 10.1002/dc.2041, PubMed 11599103

Publications 2000

Berner HS, Davidson B, Berner A, Risberg B, Kristensen GB, Trope CG, Van de Putte G, Nesland JM (2000)
Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma--diagnostic and prognostic implications
18 (2), 197-202
DOI 10.1023/a:1006711320107, PubMed 11235996

Berner HS, Davidson B, Berner A, Risberg B, Nesland JM (2000)
Differential expression of CD44s and CD44v3-10 in adenocarcinoma cells and reactive mesothelial cells in effusions
Virchows Arch., 436 (4), 330-335
DOI 10.1007/s004280050455

Davidson B, Berner A (2000)
[Serous effusions]
120 (3), 367-72
PubMed 10827531

Davidson B, Berner A, Nesland JM, Risberg B, Berner HS, Trope CG, Kristensen GB, Bryne M, Florenes VA (2000)
E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions
J. Pathol., 192 (4), 460-469

Davidson B, Berner A, Nesland JM, Risberg B, Kristensen GB, Trope CG, Bryne M (2000)
Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: Evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions
Hum. Pathol., 31 (9), 1081-1087
DOI 10.1053/hupa.2000.9776

Davidson B, Goldber I, Lerner-Geva L, Gotlieb WH, Ben-Baruch G, Novikov I, Kopolovic J (2000)
Expression of topoisomerase II and Ki-67 in cervical carcinoma - clinicopathological study using immunohistochemistry
APMIS, 108 (3), 209-215
DOI 10.1034/j.1600-0463.2000.d01-46.x

Davidson B, Gotlieb WH, Ben-Baruch G, Kopolovic J, Goldberg I, Nesland JM, Berner A, Bjamer A, Bryne M (2000)
Expression of carbohydrate antigens in advanced-stage ovarian carcinomas and their metastases - A clinicopathologic study
Gynecol. Oncol., 77 (1), 35-43
DOI 10.1006/gyno.1999.5708

Davidson B, Gotlieb WH, Ben-Baruch G, Nesland JM, Bryne M, Goldberg I, Kopolovic J, Berner A (2000)
E-cadherin complex protein expression and survival in ovarian carcinoma
Gynecol. Oncol., 79 (3), 362-371
DOI 10.1006/gyno.2000.5964

Risberg B, Davidson B, Dong HP, Nesland JM, Berner A (2000)
Flow cytometric immunophenotyping of serous effusions and peritoneal washings: comparison with immunocytochemistry and morphological findings
53 (7), 513-7
DOI 10.1136/jcp.53.7.513, PubMed 10961174

Publications 1999

Barker P, Campbell P, Davidson B (1999)
From the ashes of experience: reflections on madness survival and growth
Whurr publishers, London, 192 s.
BIBSYS 040599426, ISBN 1-86156-120-2

Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM, Berner A, Bryne M, Reich R (1999)
High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma
Clin. Exp. Metastasis, 17 (10), 799-808
DOI 10.1023/A:1006723011835

Davidson B, Goldberg I, Kopolovic J, Lerner-Geva L, Gotlieb WH, Ben-Baruch G, Reich R (1999)
MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma - A clinicopathologic study using immunohistochemistry and mRNA in situ hybridization
Gynecol. Oncol., 73 (3), 372-382
DOI 10.1006/gyno.1999.5381

Davidson B, Risberg B, Berner A, Smeland EB, Torlakovic E (1999)
Evaluation of lymphoid cell populations in cytology specimens using flow cytometry and polymerase chain reaction
Diagn. Mol. Pathol., 8 (4), 183-188
DOI 10.1097/00019606-199912000-00003

Davidson B, Risberg B, Kristensen G, Kvalheim G, Emilsen E, Bjamer A, Berner A (1999)
Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies - Evaluation of five epithelial markers
Virchows Arch. Int. J. Pathol., 435 (1), 43-49
DOI 10.1007/s004280050393

Liokumovich P, Goldberg I, Davidson B, Gotlieb WH, Zahavi T, Ben-Baruch G, Reder I, Kopolovic J (1999)
Expression of metalloproteinases endometrial stromal sarcoma: immunohistochemical study using image analysis
J. Clin. Pathol., 52 (3), 198-202
DOI 10.1136/jcp.52.3.198

Publications 1998

Barker PJ, Davidson B (1998)
Psychiatric nursing: ethical strife
Arnold, London, XVIII, 359 s.
BIBSYS 960847499, ISBN 0-340-62523-6

Davidson B, Goldberg I, Liokumovich P, Kopolovic J, Gotlieb WH, Lerner-Geva L, Reder I, Ben-Baruch G, Reich R (1998)
Expression of metalloproteinases and their inhibitors in adenocarcinoma of the uterine cervix
Int. J. Gynecol. Pathol., 17 (4), 295-301
DOI 10.1097/00004347-199810000-00002